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ABSTRACT 
 
There is a large amount of evidence indicating that oxidative stress and glycation play a crucial role in 
aging as well as in neurodegenerative and cardiovascular diseases. Oxidative stress is linked with 
reactive oxygen species (ROS), whose harmful effects can lead to several pathological conditions like 
vascular alterations, diabetes complications and inflammation. Moreover, ROS and oxidative stress 
can directly contribute to glycation reactions with the formation of reactive α-oxoaldehydes and 
advanced glycation end-products (AGEs). The glycation process is characterized by non-enzymatic 
reactions between aldehyde or keto groups of sugars and free amino-residues of proteins, which lead 
to the formation of AGEs. Glycation and AGEs cause the irreversible modification of the proteins 
structure and the consequent loss of their functionality, causing detrimental effect in vasculature. 
Thus, it can be reasonable that compounds which counteract the effect of oxidative stress and 
glycation may assume an important role in the prevention of vascular damage. Natural phenolic 
compounds and flavonoids have received attention for their biological effects, such as antioxidant 
and antiglycative activities. Despite the health claims of polyphenols, it is known that their 
bioavailability can vary dramatically depending on many factors. The effects of the polyphenols, and 
of their in vivo circulating metabolites, will ultimately depend on the extent to which they associate 
with cells, either by interactions at the membrane or more importantly by their cellular uptake. 
Therefore, in order to assess the potential activity of natural polyphenols, it is primarily important to 
evaluate the intestinal permeability and bioavailability. In this research, human colorectal carcinoma 
cells (HT-29) were used as experimental model of intestinal cells, to evaluate the polyphenols ability 
to cross the cellular membrane and permeate into the cell. The polyphenols studied in this research 
are characteristic phytoconstituents of several medicinal plants widely used in traditional medicine 
such as: baicalein (from Scutellaria baicalensis G.), eupatorin (Eupatorium semiserratum DC.), 
galangin (Alpinia officinarum L.), magnolol (Magnolia officinalis L.), myricetin (Myrica rubra S. Z.), 
oleuropein (Olea europaea L.), and silybin (Silybum marianum L.). 
The aims of the PhD project were firstly to evaluate the HT-29 intestinal cells permeability of natural 
compounds, and secondly, to investigate the in vitro antiglycation activity of polyphenols and their 
activity against endothelial cellular damage related to oxidation and glycation, using HUVEC cells as 
experimental model for endothelium function. The results showed that the ability of polyphenols to 
cross the HT-29 cell membrane depends on many factors, including molecular size and hydrophilic 
properties of each compound. The flavonoids baicalein, eupatorin and galangin were able to cross 
the HT-29 cell membranes and undergo biotransformation process; conversely, oleuropein seemed 
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to not been taken up in the HT-29 cells. The results of AGEs determination showed that most of the 
polyphenols, at the higher concentration, displayed antiglycative activity in all experimental 
conditions, and that baicalein, eupatorin and galangin showed the highest activity in counteract the 
AGEs formation.  
In the experimental model involving HUVEC, the aim was to evaluate the potential role of several 
compounds related to hyperglycemia and glycation, such as glycated albumin, glyoxal and glucose at 
high concentration, in inducing cytotoxicity and oxidative stress. Moreover, the antioxidant activity of 
the selected natural compounds against the oxidative stress induced by those factors was assessed 
using the DCFH-DA assay. The results from ROS detection assay showed that the glycation products 
known as glycated albumin and glyoxal were not able to directly induce oxidative stress in HUVEC in 
the assay conditions, whereas glucose at high concentration displayed an effect of oxidative stress 
induction. Therefore, high glucose was used as oxidative stressor in the polyphenols evaluation 
assay. Baicalein, eupatorin and galangin were selected as natural compounds with a potential 
antioxidant activity, and their activity on ROS formation in HUVEC induced by high glucose was 
evaluated. The highest antioxidant activity was seen after the pre-treatment with the polyphenols at 
the concentration of 5 μM. 
All together, the results obtained motivate further researches on the activities of polyphenols against 
oxidative and glycative damages in order to understand their potential role in the prevention of 
vascular diseases.  
  
 - 3 - 
 
Abbreviations 
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1. INTRODUCTION 
 
1.1. Vascular disease and diabetes 
Vascular disease and diabetes are chronic diseases characterized by long duration and slow 
progression. Cardiovascular diseases (CVDs) are considered the first cause of death globally: an 
estimated 17.5 million people died from CVDs in 2012, representing 31% of all global deaths (World 
Health Organization - WHO, 2016). The deaths caused by CVDs include the conditions of concurrent 
diabetes, because of the higher risk of cardiovascular events in diabetic patients; in particular, they 
have a 2-3 fold increased risk of heart attack and strokes. Most CVDs can be prevented by addressing 
behavioral risk factors such as tobacco use, unhealthy diet and obesity, and people who are at high 
risk for cardiovascular complications need early detection and management of different parameters 
(hyperglycemia, hyperlipidemia, and hypertension) which could help prevention and an appropriate 
treatment of these diseases. 
Diabetes mellitus is considered one of the most common chronic metabolic diseases in nearly all 
countries, and in particular type-2 diabetes represents a multifactorial proatherogenic disease 
involving various aspects of metabolic syndrome, a combination of hyperglycemia, hyperlipidemia, 
obesity and hypertension (Beckman et al., 2002). Type 2 diabetes may remain undetected for many 
years and its diagnosis is often made when the disease is in a later stage, and the complications have 
already occurred. Diabetics have a 2- to 4-fold higher risk for cardiovascular events, and nearly 80% 
of diabetes-associated deaths are caused by CVD (WHO, 2016). The vascular diabetic complications 
are related to prolonged exposure to hyperglycemia, as well as other risk factor such as hypertension 
and dyslipidemia. Diabetes-related macrovascular complications are mainly represented by 
atherosclerotic disease and its sequelae, whereas microvascular complications can cause 
rethinopathy and nephropathy, up to blindness and renal insufficiency (fig. 1) (Creager et al., 2003). 
 
1.1.1. Microvascular complications of diabetes 
Diabetic retinopathy may be the most common microvascular complication of diabetes. The risk of 
developing diabetic retinopathy or other microvascular complications of diabetes depends on both 
the duration and the severity of hyperglycemia. Development of diabetic retinopathy in patients with 
type 2 diabetes was found to be related to both severity of hyperglycemia and presence of 
hypertension (Fowler, 2008). The exact mechanism by which diabetes causes retinopathy remains 
unclear, but several theories have been postulated to explain the typical course and history of the 
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disease (Vithian & Hurel, 2010). It occurs following hyperglycaemia-mediated damage within the 
retinal microvasculature. This earliest damage causes basement membrane thickening, increased 
capillary permeability and the formation of microaneurysms. These changes lead to intravascular 
coagulation, resulting in retinal ischaemia which drives the formation of new vessels within the 
retina; these new vessels are fragile and may rupture causing retinal bleeds and, if left untreated, up 
to retinal detachment. Furthermore, the lack of lymphatic drainage within the retina causes fluid 
accumulation resulting in macular edema. All these processes can cause rapid vision loss and the 
decrease of the quality of life of the diabetic patient (King et al., 1994). 
 
 
Figure 1. The major diabetic complications: microvascular and 
macrovascular complications. From: Diabetes Atlas 3rd Ed, 
2006. 
 
 
Diabetic nephropathy occurs in 30–40% of patients within 25 years. Currently, diabetic nephropathy 
is the leading cause of chronic kidney disease in Western societies (Ritz & Orth, 1999). Diabetic 
nephropathy arises from the combination of hyperglycemia and hypertension driving glomerular 
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damage. This pathology is a clinical syndrome characterized by persistent albuminuria, progressive 
decline in the glomerular filtration rate and elevated arterial blood pressure. Microalbuminuria is the 
first step towards developing proteinuria, which is also a marker of vascular endothelial dysfunction. 
The pathological changes involve thickening of glomerular basement membrane, and the increase of 
the intraglomerular hypertension causes glomerular sclerosis. Furthermore, increase of matrix 
production and glycation of matrix proteins can occur. The resulting glomerular hyperfiltration leads 
to subsequent progressive loss of renal function (Gnudi et al., 2003). Good evidence suggests that 
early treatment delays or prevents the onset of diabetic kidney disease. This has consistently been 
shown in both type 1 and type 2 diabetes mellitus (Vithian & Hurel, 2010). 
Diabetic neuropathy refers to a spectrum of various neurological disorders associated with diabetes 
(Boulton et al., 2005). Diabetic neuropathy affects all peripheral nerves including pain fibers, motor 
neurons and the autonomic nervous system. The most common form is a distal, symmetrical 
sensorimotor neuropathy which may be asymptomatic; other symptoms may include dysesthesia, 
erectile dysfunction and postural hypotension, and the main sequel of neuropathy is foot deformity, 
ulceration and Charcot arthropathy (Sohn et al., 2010). The combination of neuropathy, arteriopathy 
and infection are the driving factors behind most diabetic foot amputations. 
 
1.1.2. Macrovascular complications of diabetes 
The major pathological mechanism in diabetes-related macrovascular complications is 
atherosclerosis. Studies have shown that adults with diabetes have a 2-3-fold increased risk of heart 
attacks and strokes, and it is estimated that 75-80% of diabetic adults die from complications of 
atherosclerosis. This is probably due because the progression of atherosclerotic lesions is accelerated 
by diabetes (Suzuki et al., 2001). Atherosclerosis results from chronic inflammation and injury to the 
endothelium and arterial wall in the peripheral vascular system (Lusis, 2000). The initial step is the 
modification of low density lipoprotein (LDL), caused by oxidation and glycation process, which leads 
to the formation of oxidated LDL (ox-LDL) and glycated LDL (gly-LDL). The LDL modification triggers a 
chain of metabolic responses, the first of which is the adhesion of monocytes to endothelial cells 
through the link with adhesion molecules as VCAM-1 (Vascular Cell Adhesion Molecule 1), ICAM-1 
(InterCellular Adhesion Molecule 1) and E-selectin, followed by their transmigration and infiltration 
into the subendothelial compartment. Under the influence of IL-1 (interleukin 1) from endothelium, 
infiltrated monocytes differentiate into macrophages, which start to avidly take up modified LDL via 
the scavenger receptor, ultimately leading to foam cells formation (fig. 2) (Di Marco et al., 2014). The 
uptake of ox-LDL induces macrophages to produced MSCF (Macrophages Colony Stimulating Factor), 
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which stimulates macrophages proliferation and increase of IL-2 and TNFα (Tumor Necrosis Factor α), 
which in turn stimulate VCAM-1 expression on the endothelial surface. VCAM-1 promotes the 
adhesion of circulating T-lymphocytes to endothelial cells and their migration in the subendothelial 
compartment. Vascular smooth muscle cells (VSMC) proliferation is the consequence of interferon-γ 
(IFN-γ) produced by T-lymphocytes in the arterial wall, and it is followed by elaboration of the 
extracellular matrix and accumulation of cross-linked collagen and proteoglycans. The net result of 
this process is the formation of a lipid-rich atherosclerotic lesion with a tick fibrous cap (Lusis, 2000).  
 
 
 
Figure 2. Hyperglycemia, hyperlipidemia and oxidative stress associated 
to diabetes lead to ox-LDL uptake, increase expression of adhesion 
molecules, macrophages migration into the intima and foam cells 
formation, to endothelial dysfunction and atherosclerotic plaque 
formation. From: Di Marco, 2014. 
 
 
The mechanism by which diabetes is linked with vascular disease is not completely defined, but 
evidences suggest a strong association between CVDs and diabetes. One mechanism by which high 
glucose condition may enhance the atherosclerotic process involves activation of NF-kB (nuclear 
factor kappa-light-chain-enhancer of activated B cells), which leads to the expression of inflammatory 
genes and adhesion molecules that facilitate monocyte adhesion to endothelial cells (Yan et al., 
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1994). In addition, there is evidence of increase platelet adhesion and hypercoagulability in type 2 
diabetes. Impaired NO (Nitric Oxide) generation and increased free radical formation in platelets, as 
well as altered calcium regulation, may promote platelet aggregation. In patients with diabetes, 
fibrinolysis may be impaired by elevated levels of PAI-1 (Plasminogen Activator Inhibitor type 1), and 
both increased coagulability and impaired fibrinolysis could increase the risk of vascular occlusion 
and other complications (Beckman et al., 2002). 
In vitro experimental data from literature show that, when normal aortic rings are incubated in a 
hyperglycemic condition, endothelium-dependent relaxation is impaired, suggesting that 
hyperglycemia decreases endothelium-derived NO production (Tesfamariam et al., 1991). Other 
research studies suggest that hyperglycemia induces a series of cellular events that increase the 
production of reactive oxygen species (ROS, such as superoxide anion) that inactivate NO to form 
peroxynitrite (Beckman et al., 2002). Moreover, diabetes heightens migration of vascular smooth 
muscle cells into early atherosclerotic lesions, where they replicate and produce extracellular matrix, 
as important steps in mature lesion formation. Studies from literature indicate that hyperglycemia 
may play a role in the accelerated atherosclerosis and smooth muscle accumulation in the diabetic 
animals. Thus, the observed effects on VSMC may be mediated by combination of hyperglycemia 
with other factors, like hyperlipidemia and hypertension, which represent concurrent conditions in 
diabetic patients (Suzuki et al., 2001).  
 
1.1.3. Molecular mechanism of diabetes-related complications 
The pathogenesis of diabetes-related vascular complications is complex, and several molecular 
mechanisms related to hyperglycemia are involved. Hyperglycemia could contribute to the 
development of vascular injury through increased polyol pathway, PKC activation, hexosamine 
pathway, glycation and AGEs formation, oxidative stress and ROS generation (Brownlee, 2001). 
 
1.1.3.1 Polyol pathway 
The first molecular mechanism that was discovered was the polyol pathway, described in peripheral 
nerve in the 1966 Science paper (Brownlee, 2005; Gabbay et al., 1966). In physiological glucose 
condition, only a small fraction of glucose is metabolized through this pathway, whereas in diabetic 
states, augmented intracellular glucose levels can cause an increased flux through it. The polyol 
pathway is a cellular metabolic pathway which consists of two steps (fig. 3). The first involves the 
enzyme aldose reductase, which has the function of reducing aldehydes to inactive alcohols (it 
 - 10 - 
 
reduces glucose to sorbitol). During this process, NADPH acts as cofactor. In the second step, the 
enzyme sorbitol dehydrogenase oxidizes sorbitol to fructose, using NAD+ as cofactor. Aldose 
reductase has low affinity for glucose, and, at the physiological glucose concentrations found in non-
diabetics, metabolism of glucose through this pathway is a very small percentage of total glucose 
use. 
 
 
 
Figure 3. Polyol pathway: the enzyme aldose reductase 
reduces aldehydes and glucose to sorbitol, with NADPH 
as cofactor. From: Brownlee, 2001. 
 
 
In hyperglycemic environment, however, increased intracellular glucose results in its increased 
enzymatic conversion to the polyalcohol sorbitol, with concomitant decrease of NADPH. In 
experimental conditions, flux through this pathway during hyperglycemia varies from 33% of total 
glucose in the rabbit lens to 11% in human erythrocytes. Thus, the contribution of this pathway to 
diabetic complications may be species, site and tissue dependent (Brownlee, 2001). The increased 
flux of glucose in the polyol pathway determines the augmented consumption of NADPH. Since 
NADPH is also the essential cofactor for the regeneration of reduced glutathione (GSH), a critical 
intracellular antioxidant, the decrease of cellular NADPH changes the intracellular redox balance 
resulting in the reduced production of nitric oxide and increased oxidative stress. Decreased levels of 
GSH have in fact been found in the lenses of transgenic mice that overexpress aldose reductase, and 
this is the most likely mechanism by which increased flux through the polyol pathway has deleterious 
consequences. The effect of aldose reductase inhibition on diabetic neuropathy has, however, been 
confirmed in humans in a rigorous multi-dose, placebo-controlled trial with the potent aldose 
reductase inhibitor Zenarestat, though its development was terminated (Greene et al., 1999). 
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1.1.3.2. Protein kinase C (PKC) activation 
Hyperglycemia increases diacylglycerol (DAG) content, which activates β and δ isoforms of PKC. 
Activation of PKC has a number of pathogenic consequences by affecting expression of endothelial 
nitric oxide synthetase (eNOS), endothelin-1 (ET-1), vascular endothelial growth factor (VEGF), 
transforming growth factor-β (TGF-β) and plasminogen activator inhibitor-1 (PAI-1), and by activating 
NF-kB and NAD(P)H oxidases (Brownlee, 2001). Protein kinase C is a family of protein kinase enzymes 
with 15 isoforms that are involved in the regulation of protein function. Nine of these 15 PKC 
isoforms are activated by a lipid second-messenger, diacylglycerol, and the other PKC isoforms can 
also be activated by intracellular ROS in the absence of DAG. The regulatory domain of these PKC 
isoforms contains 2 pairs of zinc fingers with 6 cysteine residues and 2 zinc atoms, which can be 
oxidized by intracellular ROS. Oxidation alters zinc-finger conformation and activates PKC (Cosentino-
Gomes et al., 2012). Hyperglycemia and elevated intracellular glucose levels increase DAG de novo 
synthesis in a variety of diabetic target tissue, and primarily activate the β and δ isoforms of PKC. 
Many cellular changes involved in diabetic vascular disease, as endothelial dysfunction, increased 
vascular permeability and impaired angiogenesis, have been linked to PKC activation. Data from 
literature show that hyperglycemia-induced activation of PKC-β promotes vascular inflammation and 
atherosclerosis in diabetic ApoE -/- mice by augmented expression of inflammatory mediators. 
Diabetic mice showed increased plaque formation, cholesteryl ester content, and macrophage 
infiltration (Kong et al., 2013). Abnormalities in renal blood flow and vascular smooth muscle cells 
functions are linked to hyperglycemia-induced PKC-β activation, perhaps by decrease of NO 
production by eNOS and increase expression of the vasoconstrictor endothelin-1. Moreover, PKC-α 
activation mediates increased permeability of endothelial cells induced by high glucose in cultured 
cells (Hempel et al., 1997). Hyperglycemia-induced activation of PKC has also been implicated in the 
overexpression of the fibrinolytic inhibitor PAI-1, the activation of NF-kB in cultured endothelial cells 
and vascular smooth muscle cells, and in the regulation and activation of various membrane-
associated NAD(P)H-dependent oxidases (Yerneni et al., 1999). 
 
1.1.3.3. Hexosamine pathway 
The hexosamine pathway causes reversible post-translational modification of intracellular protein. 
The O-linked attachment of β-N-acetylglucosamine (O-GlcNAc) to serine/threonine residues of 
proteins is a dynamic and reversible process that is an essential signal transduction mediator in all 
cells (fig. 4). O-GlcNAc serves as a nutrient/stress sensor regulating cellular homeostasis by altering 
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signaling, transcription, metabolism, organelle biogenesis, cytoskeletal dynamics, and apoptosis 
(Hardivillé & Hart, 2014).  
 
 
 
Figure 4. In hyperglycemic condition, the flux of 
glucose through the hexosamine pathway is 
increased. From: Brownlee, 2001. 
 
 
 
In normal condition, the intracellular glucose is metabolized through glycolysis, given first glucose-6-
phosphate and then fructose-6-phosphate, following the glycolytic pathway. However, in 
hyperglycemic condition, the increased fructose-6-phosphate is directed to a signaling pathway in 
which it is converted to glucosamine-6-phosphate and finally to UDP (uridine diphosphate) N-acetyl 
glucosamine. The enzyme O-GlcNAc transferase (OGT) uses UDP-GlcNAc to transfer N-
acetylglucosamine to a variety of proteins, resulting in increased protein modification by N-
acetylglucosamine. Thus, a protein over-modification induced by GlcNAc results in pathologic 
changes in gene expression. For example, increased modification of the transcription factor Sp1 
results in increased expression of transforming growth factor-β1 and plasminogen activator inhibitor-
1, both of which are detrimental for diabetic blood vessels (Marsh et al., 2014). It has been reported 
that hyperglycemia increased O-GlcNAcylation of endothelial NOS (eNOS) in bovine aortic 
endothelial cells, which was associated with a decrease in phosphorylation at Ser-1177, the site 
responsible for activation of the enzyme. The resultant increased protein modification by O-GlcNAc 
was responsible for decreased endothelium-dependent relaxation of the coronary arteries. In human 
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arterial endothelial cells, activation of eNOS by phosphorylation at Serine 1177 is inhibited directly by 
hyperglycemia-induced O-GlcNAcylation at this site (Du et al., 2001). 
 
1.1.3.4. Glycation and AGEs formation 
The non-enzymatic glycation of proteins is a process that links chronic hyperglycemia to 
physiopathological changes related to chronic diabetes complications. Glycation is characterized by 
non-enzymatic reactions between aldehyde or keto groups in sugars and dicarbonyl compounds, and 
free amino-residues in proteins, that lead to the formation of unstable adducts and Amadori 
compounds, up to the production of compounds known as Advanced Glycation End-products (AGEs) 
(fig. 5). Since its first description by Maillard in 1912, the link between glycation and various 
pathologies in the human body, including aging and diabetes, have been intensively studied.  
 
 
 
Figure 5. The glycation reaction schematically represented as the reaction between the carbonyl group of 
glucose and amino group of the lysine residue on a protein. All the main glycation steps are represented: Schiff 
base formation, Amadori products, and protein cross-links. From: Ahmed et al., 2003. 
 
 
Glycation is a multistep reaction and three stages are recognized. The first step starts with the rapid 
formation of a non-stable Schiff base between a reducing sugar, as glucose, and the free amino 
group of lysine and arginine of proteins, nucleic acids or lipids. Then, following rearrangement leads 
to the formation of a more stable ketoamine (Amadori product), as fructosamine; all these steps are 
reversible. In the second stage, oxidation and dehydration reactions occur and Amadori products 
degrade into very reactive carbonyl compounds (glyoxal, methylglyoxal, 3-deoxyglucosone). These 
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reactive dicarbonyls can act as propagators and further react with free amino groups of proteins 
starting a new glycation process. The third stage involve oxidation, dehydration and cyclization 
reactions, up to the formation of the yellow-brown, often fluorescent, AGEs which are irreversible 
products that accumulate on long-living protein and, when formed at critical sites in enzymes or 
proteins, they may be associated with enzyme inactivation or protein altered function (Vistoli et al., 
2013; Wautier & Schmidt, 2004). 
Products that could alter protein structure and function are cross-linked AGEs, hydroimidazolone and 
lysine adducts; the best known of these compounds are GOLD (glyoxal-derived lysine dimer), MOLD 
(methylglyoxal-derived lysine dimer), DOLD (3-deoxyglucosone-derived lysine dimer), pentosidine 
and CML (carboxy-methyl-lysine), (Ahmed & Thornalley, 2003). 
Glycation becomes relevant when it involves long-living proteins in the human body, impairing their 
function and contributing to diseases, such as diabetic retinopathy and atherosclerosis. AGEs are 
found in increased amounts in diabetic retinal vessels and renal glomeruli (Horie et al., 1997; Stitt et 
al., 1997).  
Three main mechanisms by which AGEs cause tissue damage are recognized: intracellular glycation, 
cross-link formation, and interaction with specific cellular receptors (fig. 6), (Brownlee, 2005). AGEs 
accumulate rapidly inside macrophages, endothelial cells and vascular smooth muscle cells: in 
endothelial cells exposed to high glucose, intracellular AGE formation occurs within a week 
(McPherson et al., 1988). The AGEs formation on intracellular proteins determines changes in their 
structure and alteration in function. Increased glycation of intracellular proteins in endothelial cells 
exposed to diabetic levels of hyperglycemia results in altered function of protein that regulate 
endothelial cells growth; basic fibroblast growth factor has been recognized one of the main AGE-
modified proteins in endothelial cells (Giardino et al., 1994). 
The AGE precursors formed inside the cells can diffuse outside the cells and modify extracellular 
matrix proteins (Charonis et al., 1990; McLellan et al., 1994). The mechanism of cross-link formation 
is non-receptor dependent and occurs especially on proteins with a slow turnover rate. The most 
important extracellular modification is abnormal cross-link on collagen and extracellular matrix 
proteins. The structural tissue modifications occurred in chronic complications of diabetes, such as 
vascular and arterial stiffening and basement membrane thickening, are related to structural and 
functional changes on collagen induced by glycation. Glycation of laminin and type I and type IV 
collagens, key molecules in the basement membrane, causes inhibited adhesion to endothelial cells 
for both matrix glycoproteins. In addition, AGE compounds in collagen may also trap macromolecules 
such as lipoproteins, immunoglobulin and albumin, contributing to vessel occlusion in atherosclerosis 
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(Lapolla et al., 2005). In the extracellular compartment, it is reported that glycation can also occurr 
on lipids and lipoproteins, leading to the formation of gly-LDL. Data from literature confirms that gly-
LDL reduces nitric oxide production and suppresses uptake and clearance of LDL through its receptor 
on endothelial cells (Goldin et al., 2006). 
 
 
 
 
Figure 6. The extracellular and intracellular effects of AGEs. The formation of AGEs on extracellular 
collagen and laminin alters the matrix structure and increase stiffness. AGEs that bind to RAGE on 
endothelial cells surface, start a signaling cascade with pro-oxidant and pro-inflammatory effects. From: 
Goldin, 2006. 
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In particular, AGEs play a physio-pathological role through the binding of specific receptors known as 
RAGE (Receptor for Advanced Glycation End-products). RAGE is a multiligand transmembrane 
receptor belonging to the immunoglobulin superfamily (Neeper et al., 1992; Schmidt et al., 2001). 
RAGE is widely localized in many cell types, and it is expressed on vascular smooth muscle cells, 
macrophages, fibroblasts, T-lymphocytes and endothelial cells. This receptor is expressed at low 
physiological levels in tissues and vasculature, but it can be abnormally up or down-regulated in 
pathological conditions, depending on ligand and signaling activation. RAGE is upregulated when AGE 
ligands accumulate, an example of positive-feedback activation, and this upregulation effect occurs 
on cells such as endothelial cells, smooth muscle cells, and mononuclear phagocytes in diabetic 
vasculature (Schmidt et al., 2001). RAGE is considered a pattern recognition receptor, because of its 
ability to bind several ligands in addition to AGEs: RAGE can bind proinflammatory cytokine-like 
mediators of the S100/calgranulin family, amphoterin (also known as high-mobility group B1, 
HMGB1), and amiloid-beta protein (Chavakis et al., 2003).  The binding of RAGE with AGEs, as well as 
with S100 calgranulins and HMGB1, trigger inflammatory pathways.  In the vasculature, the main 
pathological consequence of AGEs interaction with RAGE is the induction of intracellular ROS, the 
generation of which seems to be linked to the activation of NADPH-oxidase. An important key target 
of RAGE signaling is NF-kB. Upon RAGE stimulation, the transcription factor NF-kB is translocated to 
the nucleus, where it increases transcription of several different proteins, including endothelin-1, 
VCAM-1, ICAM-1, E-selectin, tissue factor and RAGE itself (Goldin et al., 2006). In HUVEC, inhibitors of 
NF-kB greatly reduce high glucose-induced monocyte adhesion, suggesting that the activation of NF-
kB is essential in AGE-induced monocyte adhesion and migration (Morigi et al., 1998). 
In diabetes, the AGE-RAGE interaction may result in a long-lasting sustained activation of NF-kB, in 
the absence of decreased IκBα, via a protein synthesis-dependent pathway and sustained 
translocation of NF-kB from the cytoplasm into the nucleus. This mechanism may contribute to the 
persistent NF-κB activation observed in hyperglycemia (Bierhaus et al., 2001). Studies have shown 
that AGEs cause increased expression of macrophage scavenger receptor (MSR) and CD36 receptors, 
leading to increased ox-LDL uptake and foam cell formation. AGEs may contribute to the expression 
of oxidized LDL (ox-LDL) receptors in human monocyte-derived macrophages. Activation of 
monocytes by AGE-modified human serum albumin also leads to expression of IL-1β and TNFα mRNA 
(Webster et al., 1997). 
Interestingly, RAGE is not the only receptor for AGEs, other receptors known to recognize and bind 
AGEs include class A macrophage scavenger receptors (MSRs), oligosaccharyl transferase-48 (OST48, 
also known as AGE-R1), 80 K-H phosphoprotein (or AGE-R2), galectin-3 (AGE-R3), lectin-like oxidized 
low density lipoprotein receptor-1 (Lox-1), fasciclin EGF-like, laminin-type EGF-like, and link domain-
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containing scavenger receptor-1/2 (FEEL1/2) and CD36. Nevertheless, they have not been shown to 
transduce cellular signals after engagement by AGEs. Instead, they may cause the clearance and 
possible detoxification of AGEs (Bucciarelli et al., 2002). 
 
1.1.3.5. Oxidative stress and ROS formation 
The hyperglycemia-related process besides all the cited mechanisms of vascular damage (polyol 
pathway, PKC activation, enhanced flux through hexosamine pathway, glycation and AGEs formation) 
can be recognized as the overproduction of superoxide by the mitochondrial electron transport chain 
(Shah & Brownlee, 2016). Enhanced intracellular glucose transport and oxidation leads to 
mitochondrial overproduction of superoxide (fig. 7).  Many studies have shown that diabetes and 
hyperglycemia increase oxidative stress, but the specific pathway is not clear. It has now been 
established that all of the different pathogenic mechanisms described above derive from a single 
hyperglycemia-induced process: the overproduction of superoxide by the mitochondrial electron-
transport chain. Superoxide is the initial oxygen free radical formed by the mitochondria, which is 
then converted to other more reactive species that can damage cells in numerous ways (Wallace, 
1992).  
 
 
Figure 7. The overproduction of ROS by the mitochondrial 
electron-transport chain is the initial step of oxidative 
stress, which could lead to lipid peroxidation, protein 
oxidation and DNA damage, up to cellular dysfunction 
(Baughman & Mootha, 2006). 
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The mitochondrial isoform of the enzyme SOD degrades this oxygen free radical to hydrogen 
peroxide, which is then converted to H2O and O2 by other enzymes. In primary arterial endothelial 
cells in culture, intracellular high glucose concentration increases the voltage across the 
mitochondrial membrane above the critical threshold necessary to increase superoxide formation 
and, subsequently, increases production of ROS (Giacco & Brownlee, 2010).  Evidences indicate that 
the mitochondria are required for the initiation of hyperglycemia-induced superoxide production, 
and that this higher radical production may then amplify the original damaging effect of 
hyperglycemia, including redox changes, NADPH oxidase, and uncoupled eNOS. The initiating role of 
mitochondrial ROS is suggested by the observation that cells lacking mitochondrial electron transport 
chain function (ρ0 cells)53 fail to increase ROS production in response to high glucose (Brownlee, 
2005). The excess of ROS production leads to cellular dysfunction, inflammation, apoptosis, and 
fibrosis in cells exposed to high glucose flux. The importance of ROS generation in these processes is 
confirmed by the fact that cellular damage can be prevented when the transgenic expression of the 
enzyme superoxide dismutase determined the reduction of hyperglycemia-mediated ROS generation 
(Shen et al., 2006). 
In cardiovascular physiology, ROS production occur also in normal conditions, and ROS species act as 
signaling molecules essential for cellular homeostasis. Physiological level of ROS is essential for cell 
differentiation, autophagy, growth factor stimulation, and generation of physiological inflammatory 
response. In specific, low concentrations of superoxide anion (O2−•) and hydrogen peroxide (H2O2) 
are produced in cells by mitochondria and NADPH oxidases. They are controlled by endogenous 
antioxidants, manganese and copper/zinc superoxide dismutase (MnSOD, Cu/Zn SOD), catalase, and 
glutathione peroxidases. Together with nitric oxide (•NO), ROS act as cell signaling initiators, for 
example regulating VSMC contraction and relaxation (Cohen & Tong, 2010). Moreover, it is well 
known that the signal propagation upon receptor binding of growth factors such as platelet-derived 
growth factor (PDGF), epidermal growth factor, and endothelin-1, as well as cytokines such as TNFα 
and IL-1β, is mediated through the generation of O2•− and H2O2. To maintain cellular redox balance 
and prevent potential damage induced by radical species, enzymatic antioxidant defense systems 
(catalase, superoxide dismutase, glutathione peroxidase) remove and scavenge ROS. In pathological 
conditions, the increase in ROS production and the not adequate efficiency of the antioxidant 
systems lead to oxidative stress. The excessive ROS production and the oxidative stress in vascular 
compartment are believed to be crucial contributors to the pathogenesis and progression of 
diabetes-related vascular disease. Increased ROS formation leads to endothelial dysfunction, 
impaired vascular relaxation, increased VSMC growth and migration, and increased of extracellular 
matrix deposition (Brown & Griendling, 2015). 
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1.2. Natural products and polyphenols 
Nature has been a source of medicinal agents for thousands of years, and an impressive number of 
modern drugs have been isolated from natural sources, many based on their use in traditional 
medicine (Cragg & Newman, 2001). The use of plants in the traditional medicine systems of many 
cultures has been extensively documented, and these plant-based systems continue to play an 
essential role in health care: it has been estimated by World Health Organization that approximately 
80% of people worldwide rely on traditional medicines for their primary health care, and plant 
products play an important role in the health system for 20% of the population. Especially in Africa 
and some developing countries, traditional medicine is often the primary source of health care 
(Farnsworth et al., 1985; World Health Organization, 2005). 
Plant-derived natural products have importance not only in traditional medicine, but they also 
represent an interesting source for drug discovery (Newman & Cragg, 2016). Since natural products 
are made from living organisms, they possess properties that are evolutionary optimized for having 
different biological functions (for example binding to specific target proteins or other biomolecules), 
(Appendino et al., 2010). The most interesting thing is that drug discovery from nature could lead to 
the isolation of active compounds with therapeutic activity, which can be improved thanks to 
chemical and structural modifications of the starting compound. In a recent review, Newman and 
Cragg have shown that 34% of current drugs are natural-product-inspired or derived (semi-synthetic 
natural products, or active compounds inspired from nature) (Newman & Cragg, 2012). 
Plant-derived natural products approved for therapeutic use in the last thirty years (1984-2014) are 
used for the treatment of various disease conditions and modulate a large range of molecular 
targets. Drug discovery from medicinal plants in the 19th century led to the purification of several 
early drugs including aspirin, codeine, digitoxin, morphine, and quinine, which are all still widely 
used.  Moreover, still today natural products are an important source for the discovery and 
development of new drugs. The most recent plant-derived products approved as drugs by FDA are 
Veregen® (sinecatechins; green tea (Camellia sinensis L. leaf extract), Fulyzaq® (crofelemer; extract 
from the red latex of Croton lechleri Müll.Arg.), and Grastek® (Timothy grass (Phleum pretense L.) 
pollen allergen extract), (Waltenberger et al., 2016). 
Thus, medicinal plants and natural products still represent an important pool for identification of 
new pharmacological leads today. Scientific interest in plant-derived natural product-based drug 
discovery is renewing, as seen from the analysis of PubMed publications trends (Atanasov et al., 
2015). 
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Considering the huge morbidity and mortality burden related to vascular and metabolic disorders, 
there is a high interest in the discovery of novel compounds as well as novel pharmacological targets 
that might be effective in the treatment or prevention of cardiovascular and/or metabolic disorders. 
Several natural compounds have been shown to affect vascular and metabolic disorders through 
different mechanisms, such as anti-inflammatory activity, changes of blood lipid profiles, 
improvement of insulin sensitivity, or normalization of blood glucose levels (Lacroix & Li‐Chan, 2014; 
Ríos et al., 2015). Often the underlying molecular targets mediating these beneficial effects are not 
well understood. However, there are several molecular targets or pathways that are already well 
established to mediate the beneficial effects of natural compounds in the context of cardiovascular 
and metabolic disorders. Of those, the AMP-activated protein kinase (AMPK), cyclooxygenase (COX)-
1 and -2, the dipeptidyl peptidase-4 (DPP-4), the endothelial nitric oxide synthase (eNOS),  NF-kB, 
nuclear factor-erythroid 2-related factor 2 (Nrf2), (Waltenberger et al., 2016).  
The most widespread compounds present in medicinal plants which claim a potential therapeutic 
activity belong to the class of polyphenols, flavonoids, terpenes, and alkaloids.  Among these, 
flavonoids are secondary metabolites widely distributed throughout the plant kingdom with well 
known and proven antioxidant and anti-inflammatory activities (Vasanthi et al., 2012). 
In the present research, seven plant-derived polyphenols were studied for their potential activity in 
the treatment or prevention of the vascular damage induced by oxidative stress and glycation. The 
polyphenols studied in this research are from medicinal plants widely used in traditional medicine: 
baicalein (from Scutellaria baicalensis G.), eupatorin (Eupatorium semiserratum DC.), galangin 
(Alpinia officinarum L.), magnolol (Magnolia officinalis L.), myricetin (Myrica rubra S. Z.), oleuropein 
(Olea europaea L.) and silybin (Silybum marianum L.), (fig. 8). 
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Figure 8. Chemical structure of baicalein, eupatorin, galangin, magnolol, myricetin, oleuropein and silybin: 
polyphenols from medicinal plants widely used in traditional medicine. 
 
 
 
 
 
 
 
 
Baicalein 
Scutellaria baicalensis G. 
Eupatorin 
Orthosiphon stamineus B. 
Galangin 
Alpinia officinarum L. 
Magnolol 
Magnolia officinalis L. 
Myricetin 
Myrica rubra S. Z. 
Oleuropein 
Olea europea L. 
Silybin 
Silybum marianum L. 
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1.2.1. Baicalein 
Baicalein is a flavone isolated primarily from the roots of Scutellaria baicalensis G., but its presence is 
also reported in Oroxylum indicum B. Scutellaria baicalensis and Oroxylum indicum are medicinal 
plants used in Chinese and eastern traditional medicine. Scutellaria baicalensis is one of the 50 
fundamental herbs used in traditional Chinese medicine, which has been widely used as anti-
inflammatory, anti-viral, anti-bacterial and anti-cancer compound (Huang et al., 2006; Kumagai et al., 
2007). Oroxylum indicum has been used for centuries as important herbal medicine in many Asian 
countries to cure various diseases. The traditional uses of Oroxylum indicum comprise the treatment 
of fever, bronchitis, intestinal worms, asthma, inflammation and dysentery; in Traditional Chinese 
medicine, the seeds of the plant have been widely used for the treatment of cough, bronchitis, 
pharyngitis, pertussis and other respiratory disorders (Dinda et al., 2015). 
Baicalein is one of the major flavonoids present in the dried roots of Scutellaria baicalensis, and it is 
reported that possesses a multitude of pharmacological activities. Baicalein is a potent free radical 
scavenger and xanthine oxidase inhibitor, thus improving endothelial function and having 
cardiovascular protective actions against oxidative stress-induced cell injury (Huang et al., 2005). 
Many researches were conducted to study its potential role in vascular diseases and in particular its 
activity on blood pressure. The results show that baicalein lowers blood pressure in renin-dependent 
hypertension in rats, and the in vivo hypotensive effect may be partly attributed to its inhibition of 
lipoxygenase, resulting in reduced biosynthesis and release of arachidonic acid-derived 
vasoconstrictor products (El-Bassossy et al., 2014). Baicalein was studied, together with its 
glucuronide form baicalin, for the antioxidant and anti-inflammatory activities. These two flavonoids 
have shown anti-inflammatory effects and improvement of mitochondrial dysfunction through 
redox-dependent mechanisms (de Oliveira et al., 2015). In addition, it has shown that baicalin and 
baicalein protect mitochondria from oxidative stress both in vitro and in vivo. Data from literature 
show that baicalein protects different types of cells against oxidative stress, involving the inhibition 
of 12-lipoxygenase and 15-lipoxygenase.  By inhibiting 12-lipoxygenase and up-regulating Nrf2, 
baicalein blocks the increase in ROS level in NG108–15 neuroblastoma x glioma hybrid cells, which 
have been widely used to study many aspects of neuronal function and differentiation, from H2O2-
induced activation of the mitochondrial apoptotic pathway (Yeh et al., 2015). 
Regarding the research for natural products that modulate vascular inflammatory response, it has 
been found that baicalein and baicalin had anti-inflammatory effects on LPS-mediated inflammation 
in vitro and in vivo. Recent investigations showed that baicalein can exert anti-inflammatory effects 
on LPS-stimulated macrophages by inhibiting TNF-α, COX-2, and iNOS gene expression, as well as 
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inhibiting the production of NO, IL-1β, TNF-α, COX-2, iNOS, and PGE2 via estrogen receptor-
dependent pathway (Fan et al., 2013). 
Baicalein was also studied for its potential role as anti-tumor agent. Research studies reveal that 
baicalein exerts this effect by promoting the apoptosis and inhibiting the proliferation of cancer cells. 
In specific, treatment with baicalein in vitro resulted in hepatocellular carcinoma cells growth 
inhibition, with an accumulation of cancer cells in G0/G1 phase. The in vivo studies on mice carrying 
xenograft tumors showed that the treatment with baicalein determined the reduction of tumor 
weight in a dose-dependent manner (Zheng et al., 2014). 
 
1.2.2. Eupatorin 
Flavone eupatorin is isolated from Orthosiphon stamineus B., a medicinal herb used in folk medicine 
in South East Asia for the treatment of various disorders. This plant is used in traditional medicine 
and leaves are consumed as herb tea for body detoxification, to treat fever and influenza, 
rheumatism, urinary and biliary lithiasis. Extensive pharmacological investigations on various extracts 
from Orthosiphon stamineus were carried out to characterize its therapeutic potential. The results 
revealed that Orthosiphon stamineus exhibits a large spectrum of activities, including diuretic, 
antioxidant, uricosuric, anti-hypertensive, hepatoprotective, and anti-inflammatory (Olah et al., 
2003). 
The polymethoxylated flavonoids sinensetin, eupatorin and 3'-hydroxy-5,6,7,4'-tetramethoxyflavone 
are found as dominant compounds in the chloroform fraction of the extracts, and are among the 
most therapeutically important constituents (Yam et al., 2016). Studies from literature show that 
eupatorin has anti-proliferative effect against several cancer lines, including human cervical 
adenocarcinoma (HeLa), human gastric adenocarcinoma (MK-1), murine melanoma (B16F10), murine 
colon carcinoma (26-L5), or human breast cancer cell line (MDA-MB-468), (Androutsopoulos et al., 
2008; Lee et al., 2016). Anti-angiogenic activity of eupatorin was also tested, using HUVEC as 
experimental model of angiogenesis in vitro. Eupatorin determined the decrease of cell migration 
and also the decrease of the cell ability of tube formation (Dolečková et al., 2012). In addition to this, 
due to its structural similarity to known protein kinase inhibitors, the effect of eupatorin to inhibit 
representative human protein kinase was examined, and the results show that eupatorin is a non-
specific inhibitor of protein kinases (Singh & Agarwal, 2006). 
Other researches from literature set the aim to study the anti-inflammatory activity of Orthosiphon 
stamineus extracts and isolated flavonoids, including eupatorin. The studies on inflammatory gene 
expression in vitro and carrageenan-induced paw inflammation in vivo showed that flavonoids 
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eupatorin and sinensetin inhibited the expression of inflammatory mediators as PGE2, and TNFα. 
Furthermore, eupatorin and sinensetin inhibited carrageenan-induced paw inflammation (Laavola et 
al., 2012). Eupatorin seems to display also vasorelaxation effect, as seen by Yam and colleagues in 
rats aortic ring (Yam et al., 2016). 
 
1.2.3. Galangin 
Galangin is a polyphenolic compound isolated from the rhizome of Alpinia officinarum H., which is 
used as traditional herb remedy in the Middle East, for rheumatic pains and arthritis (Su et al., 2013). 
It is also used traditionally for hiccups, nausea, chronic gastritis and ulcers in the digestive tract. It has 
been reported that Alpinia officinarum has analgesic, anti-pyretic, and antimicrobic activities. The 
flavonol galangin has been studied with the aim to detect its potential antioxidant, anti-inflammatory 
and anti-cancer activity. In the context of cancer, the activity of galangin on leukemia cancer cells 
was studied. It is reported that galangin could induce a G0-G1 cell cycle arrest and decrease Bcl-2 
levels, which leads to apoptosis of imatinib-resistant Bcr-Abl expressing leukemia cell lines (Tolomeo 
et al., 2008). Furthermore, the activity of galangin on hepatocellular carcinoma was extensively 
studied.  The results from literature reveal that galangin significantly reduce the viability of 
hepatocellular carcinoma cells via mitochondrial pathway, triggering Bax translocation to the 
mitochondria and inducing overexpression of Bcl-2 (Zhang et al., 2010). The anti-cancer activity has 
been further studied, and the results reveal that galangin induced ER (endoplasmic reticulum) stress 
in liver cancer cells leading to proliferation inhibition (Su et al., 2013). 
A potential vascular activity of galangin has been hypothesized, thus, its effect on isolated rat 
thoracic aorta was examined (Morello et al., 2006). In the study, the flavonoid causes both 
concentration- and endothelium-dependent relaxation of rat thoracic aortic rings pre-contracted 
with phenylephrine. Data from literature confirm also the antioxidant activity of galangin on isolated 
rat liver mitochondria, because of its protective effect against membrane lipid preroxidation (Dorta 
et al., 2008).  
 
1.2.4. Magnolol 
Magnolol is a hydroxylated biphenyl compound isolated from the stem bark of Magnolia officinalis 
L.; this is a Chinese herb used in traditional medicine in South Korea, China and Japan for 
gastrointestinal disorders, cough, anxiety, depression, and allergic diseases (Chen et al., 2011; 
Maruyama et al., 1998).  Magnolia officinalis bark is rich in two biphenyl compounds, magnolol and 
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honokiol, that have been extensively investigated.  A large number of pharmacological activities have 
been reported for magnolol, including anti-inflammatory, antimicrobial, antioxidant, 
neuroprotective, and anti-tumor activities. In the context of the anti-inflammatory activity, magnolol 
was found to inhibit NO production in LPS-activated macrophages, and to suppress inflammatory 
cytokines production in THP-1 monocyte cells (Park et al., 2004).  Research reports that magnolol 
inhibits LPS-induced pro-inflammatory cytokines by interfering with toll-like receptor 4, and that this 
is related to the inhibition of NF-kB and MAPK signaling pathway (Fu et al., 2013). 
The beneficial effects of magnolol in the context of vascular disease have been studied, and the 
results show in vitro and in vivo evidences of a potential activity. Treatment of human aortic 
endothelial cells (HAECs) with magnolol 5 μM significantly suppresses the TNFα-induced expression 
of VCAM-1. Furthermore, in vivo, magnolol attenuates the intimal thickening and TNFα and VCAM-1 
protein expression seen in the thoracic aortas of cholesterol-fed rabbits. In addition, it inhibited the 
binding of the human monocytic cell line, U937, to TNFα-stimulated HAECs and decreased H2O2 
levels in control and TNFα-treated HAECs (Chen et al., 2002). These results suggest that magnolol 
may play an important role in the prevention of atherosclerosis. 
 
1.2.5. Myricetin 
Myricetin is a polyhydroxylated flavonol isolated from Myrica rubra S. Z., which is a traditional 
medicinal plant from Asia.  Myricetin is a common plant-derived flavonoid and is well recognized for 
its beneficial health value; it is largely used as preserving agent to extend the shelf life of foods 
containing fats, and this use is attributed to its ability to protect lipids against oxidation (Semwal et 
al., 2016). 
This polyphenol compound is considered a powerful anti-oxidant. Extensive researches from 
literature reveal that myricetin exhibits the scavenging activity towards a large number of radicals 
and ions. The inhibition of ABTS+ and DPPH radicals by myricetin was found to be polyphenol 
oxidase-dependent (Jiménez & García‐Carmona, 1999). However, other researchers reported that 
although the compound exerts a strong scavenging activity against DPPH radicals, it does not have 
activity against ROS in menadione-stressed HL-60 cells (Rusak et al., 2005). On the other hand, it was 
also found to protect cells against H2O2-induced cell damage via inhibition of ROS generation and 
activation of antioxidant enzymes at the concentration of 30 μM (Bertin et al., 2016; Kang et al., 
2010). Several studies suggested that myricetin protects tert-butylhydroperoxide (t-BHP)-induced 
oxidative stress in erythrocytes from type 2 diabetic patients (Li & Ding, 2012). Myricetin along with 
other flavonoids decreases LDL glycation and electrophoretic mobility, which reduce the 
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atherosclerotic risk of patients with diabetes mellitus (Ghaffari & Mojab, 2007). The high reactivity 
and antioxidant activity of myricetin is supposed to be due to the number of hydroxyl substituents 
present in the chemical structure. Myricetin, with its six hydroxyl groups, could be expected to have a 
strong peroxyl radical absorbing capability. 
Extensive research on the anticancer activities of myricetin has indicated that the compound is 
cytotoxic towards a spectrum of human cancer cell lines, including hepatic, skin, pancreatic and colon 
cancer cells. It is reported that myricetin possesses anti-proliferative activity against human acute 
leukemia HL-60 cells and the activity was enhanced with increasing concentration (Chang et al., 
2007). Research conducted on human lung carcinoma A549 cells reveal that myricetin inhibits 
metastasis of this cancer cells in vitro by limiting the adhesion, invasion and migration of cancer cells 
without showing cytotoxicity against normal cells (Shih et al., 2009). Other research studied the 
potential activity of myricetin against inflammation. The results show that myricetin displays anti-
inflammatory activity by inhibiting the production of LPS-induced prostaglandins (Takano-Ishikawa et 
al., 2006). At a concentration of 10 μM, myricetin inhibited NO production in endotoxin-stimulated 
RAW264.7 murine macrophages, without evident cytotoxicity (Wang et al., 2006). 
 
1.2.6. Oleuropein 
Oleuropein is a polyphenol isolated from the leaf of Olea europea L., and it is generally the most 
prominent phenolic compound in olive cultivars. A large number of researches have been conducted 
on oleuropein, and several pharmacological properties of this polyphenolic compound have been 
detected. It is reported that oleuropein possess many activities, including antioxidant, anti-
inflammatory, anti-atherogenic, anti-cancer, antimicrobial and antiviral (Tripoli et al., 2005; Visioli et 
al., 1998; Visioli et al., 2002). The antioxidant activity of oleuropein has been extensively studied, and 
the results show that its antioxidant potential is mainly related to its ability to improve radical 
stability, as assessed in vitro by the 2,2-diphenyl-1-picrylhydrazyl radical (DPPH) test, demonstrating 
antioxidant potential similar to those exerted by ascorbic acid (vitamin C) and α-tocopherol (vitamin 
E) (Visioli et al., 1998). With its catecholic structure, oleuropein is able to scavenge the peroxyl 
radicals and break peroxidative chain reactions, producing very stable resonance structures (Barbaro 
et al., 2014).  
Moreover, it is reported the protective activity of oleuropein against LDL oxidation: in vitro, 
oleuropein strongly and dose-dependently inhibits copper sulphate-induced oxidation of LDL (Visioli 
& Galli, 1994). Other authors conducted in vivo studies with rabbit fed with special diet rich in olive 
oil and oleuropein; the results indicate that the compound increases the ability of LDL to resist 
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oxidation and, at the same time, reduces the plasma levels of total, free, and esterified cholesterol. 
Furthermore, oleuropein has additional beneficial effects on several aspects of cardiovascular 
disease because of its potential anti-platelet aggregation, vasodilation, anti-ischemic and hypotensive 
properties (Coni et al., 2000). Other effects of this compound have been highlighted, in particular 
oleuropein administration has a hepatoprotective and therapeutic effect on carbon tetrachloride-
induced liver damage in mice, and a diet supplemented with oleuropein reduces hepatic steatosis 
and progression to non-alcoholic steatohepatitis in mice fed with a high fat diet (Domitrović et al., 
2012; Park et al., 2011). Several in vitro evidences have been collected demonstrating the 
antiproliferative and proapoptotic effects of oleuropein in different cancer cell lines (Casaburi et al., 
2013). 
 
1.2.7. Silybin 
Silybin is the major active constituent of silymarin, a standardized extract of the Silybum marianum L. 
fruits. Silybin itself is a mixture of two diastereoisomers, silybin A and B, present in approximately 
equimolar ratio. Silybum marianum has been largely used in traditional medicine against intoxication 
and to promote bile flow, as well as to treating liver diseases. Silybin exhibits a large number of 
pharmacological effects, especially in the liver. Several clinical trials have been conducted, and there 
are some clinical evidences that highlighted the beneficial effect of silybin for alcoholic liver cirrhosis, 
chronic hepatitis C infection, non alcoholic fatty liver disease, and strong inhibitory effects on the 
proliferation of hepatocellular carcinoma and cirrhosis-associated insulin resistance (Federico et al., 
2006; Lirussi et al., 2002; Singh et al., 2008).  Most of the biological effects of silybin have been 
attributed to its antioxidant capacity, which has been largely studied. It is reported that silybin 
inhibits and blocks the high glucose-dependent increase of intracellular superoxide production and 
NADPH-oxidase activity, protecting the cells from apoptosis (Khazim et al., 2013; Varga et al., 2004). 
In vitro studies show that silymarin has both antioxidant and anti-inflammatory effects, including 
inhibition of superoxide production in Küpffer cells, and in addition, silybin prevents hydrogen 
peroxide-induced apoptosis of endothelial cells (Dehmlow et al., 1996). In another experimental 
study of H2O2 apoptosis model, the treatment with silybin exerts in vitro radical scavenging activity 
and restored cell viability with a reduction in H2O2-induced apoptotic DNA damage, and decreased 
the expression of caspase-3 (Wang et al., 2005). In addition, there is considerable data showing 
strong inhibitory effects of silybin on the proliferation and survival of different cancer cells in vitro 
and in vivo (Singh et al., 2008). 
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2. AIM 
 
Considering the huge morbidity and mortality burden related to vascular and metabolic disorders, 
there is high interest in the discovery of plant-derived compounds that might be effective in the 
treatment or prevention of cardiovascular and/or metabolic disorders.  
The aims of this study were to investigate and evaluate: 
 the cellular uptake of several polyphenols on HT-29 cells, an experimental model of intestinal 
cells, in order to examine their ability to cross intestinal cell membrane; 
 the antiglycative activity of polyphenols against albumin glycation induced by glucose, ribose 
and glyoxal; 
 the anti-inflammatory activity of baicalein and eupatorin against the TNFα-induced VCAM-1 
expression on HUVECtert cells; 
 the effects of selected compounds involved in pathological conditions linked with 
hyperglycemia and vascular disease, like glycated albumin, glyoxal and glucose at high 
concentration, on viability and ROS formation in HUVEC; 
 the antioxidant activity of selected polyphenols against the ROS formation induced by 
glucose at high concentration in HUVEC. 
 
The polyphenols studied in this research are characteristic phytoconstituents of several medicinal 
plants widely used in traditional medicine such as: baicalein (from Scutellaria baicalensis G.), 
eupatorin (Eupatorium semiserratum DC.), galangin (Alpinia officinarum L.), magnolol (Magnolia 
officinalis L.), myricetin (Myrica rubra S. Z.), oleuropein (Olea europaea L.) and silybin (Silybum 
marianum L.). 
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3. METHODS 
 
3.1. HT-29 cells 
HT-29 is a human colorectal adenocarcinoma cell line with epithelial morphology (fig. 9). In addition 
to being a xenograft tumor model for colorectal cancer, the HT-29 cell line is also used as an in vitro 
model to study absorption, transport, and secretion by intestinal cells. Under standard culture 
conditions, these cells grow as a non-polarized, undifferentiated multilayer (Collett et al., 1996). This 
cell line was established in 1964 from the primary tumor of a 44-year-old Caucasian woman with 
colorectal adenocarcinoma. HT-29 cells were cultured in RPMI 1640 medium supplemented with 10% 
FBS, 2% glutamine and 1% penicillin/streptomycin. Cells were grown in 10 mm dish and subcultured 
when reached 80-90% confluence, using enzymatic digestion with trypsin-EDTA. The HT-29 cells were 
used as reference model of intestinal cells to study the cellular uptake of the tested polyphenols. 
 
 
 
Figure 9. Human colorectal adenocarcinoma cell line HT-29. 
 
 
 
3.1.1. HT-29 cytotoxicity assay 
The cytotoxicity assay was performed to see whether the polyphenols could be toxic for the cells at 
the concentrations chosen for the cellular uptake assay. The cellular viability after the treatment with 
the selected compound, at the concentration range of 1-10 μM, was determined using the MTT assay 
(van Meerloo, Kaspers, & Cloos, 2011). This experimental method is a colorimetric assay for 
evaluating the cellular metabolic activity. NAD(P)H-dependent cellular oxidoreductase enzymes are 
capable of reducing the tetrazolium dye MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
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bromide (yellow) to its insoluble formazan, which has a purple color. This assay could be used to 
measure cytotoxicity (loss of viable cells) or cytostatic activity (shift from proliferation to quiescence) 
of the tested compounds. 
HT-29 cells were seeded in a 96-well plate at the density of 5,000 cells/well and let grown overnight; 
the day after cells were treated with each polyphenols for 24 hours, and then an aliquot of MTT 
solution was added to each well, to reach the final concentration of 500 μg/mL. After the reduction 
of the MTT by cellular enzymes, the medium was removed and the insoluble formazan salts were 
solubilized with 2-propanol/0,33% HCl (36%). The absorbance of each purple formazan solution was 
measured using a PerkinElmer 2030 VictorTMX3, setting the wavelength at 520 nm. 
 
3.1.2. Cellular uptake in HT-29 cells 
A critical point in the debate on health effects of polyphenols is indeed their bioavailability, therefore 
the human colorectal carcinoma cells (HT-29) were used to evaluate the polyphenols ability to cross 
the cellular membrane and permeate into the cells. To assess the polyphenols cellular uptake, HT-29 
cells were seeded in 6-well plate in complete medium and grown until confluence for 48 hours.  
Then, culture medium was removed, and cells were washed with PBS and treated for three hours 
with 5 μM polyphenols solution in HBSS.  
After the incubation,  an aliquot of the extracellular solution was taken from each well  and stored at 
-20 °C for further analysis. Then the medium was removed, cells were washed two times with PBS 
and prepared for the following steps: 
a) protein quantification - the cells were lysed with 200 μL of lysis buffer (RIPA buffer) and the wells 
were washed with 200 μL of PBS; 
b) cellular uptake evaluation - the cells were collected gently scraping with PBS, centrifuged at 1200 
rpm for 5 minutes, and 500 μL of 80% methanol solution in water/0,1% acetic acid was used to 
extract the intracellular content. The cells were mixed with the methanol solution, put on ice for 15 
minutes, sonicated and centrifuged at 10,000 rpm for 10 minutes. The precipitated proteins were 
excluded and the supernatant solution kept for chromatographic analysis. 
The lysates and the intracellular extracted solution were stored at -20 °C for further analysis. 
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3.1.3. HPLC analysis 
The chromatographic analysis of extracellular and intracellular solutions was performed using a 
reverse phase HPLC system consisting of a 1525 binary HPLC pump (Waters) equipped with Waters® 
2998 Photodiode array detector, and a reversed phase C18 column Waters® Symmetry® C18 3,5 μm 
4,6 x 75 mm. Methanol/0,1% acetic acid and water/0,1% acetic acid were used as mobile phase, in 
different proportions depending on the compound tested, and an appropriate gradient elution was 
chosen for the analysis (tab. 1). All analysis were performed at room temperature (24-25°C) using a 
linear gradient and a flow rate of 1 mL/min. The amount of each polyphenol compound in the extra- 
and intracellular solutions was calculated comparing the results with the standard calibration curve. 
The last step included the analysis of the lysate protein content using the Lowry protein assay, to 
obtain the final results expressed as nmol of polyphenol per mg of cellular proteins. 
 
 
Table 1. Gradient elution set for the extra- and intracellular solution of the polyphenols uptake in HT-
29 cells; eluent A is H2O/0,1% acetic acid, eluent B is MeOH/0,1% acetic acid, flow rate 1 mL/min. 
 Baicalein Eupatorin Galangin Magnolol Myricetin Oleuropein Silybin 
Time 
(min) 
% A % B % A % B % A % B % A % B % A % B % A % B % A % B 
- 80 20 80 20 80 20 80 20 80 20 80 20 80 20 
1 80 20             
2   50 50 40 60 50 50 50 50 60 40 60 40 
6     20 80       20 80 
7 20 80 20 80 20 80   20 80   20 80 
8 20 80 20 80   20 80 20 80 20 80   
9     80 20     20 80 80 20 
10 80 20 80 20 - - 20 80 80 20 80 20 - - 
12 - - - - - - 80 20 - - - - - - 
 
 
 
3.1.4. Lowry protein assay 
The Lowry protein assay is a colorimetric assay useful for the determination of the total level of 
proteins. Under alkaline conditions, the divalent copper ion forms a complex with peptide bonds in 
which it is reduced to a monovalent ion. Monovalent copper ion and the radical groups of tyrosine, 
tryptophan, and cysteine react with Folin reagent to produce an unstable product that becomes 
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reduced to molybdenum/tungsten blue, whose intensity can be measured with a spectrophotometer 
setting the wavelength of 595 nm (Lowry et al., 1951). This assay was used to determine the protein 
content of the lysates obtained in the cellular uptake assay. 
Briefly, 100 μL of each sample were added to 1 mL of Lowry reagent (tab. 2). They were incubated for 
30 minutes, then, 100 μL of Folin reagent were added. After 30 minutes of incubation, in the dark, at 
room temperature, the absorbance of the experimental mixtures was measured using a 
spectrophotometer. The same procedure was performed using the solutions of the standard protein 
(BSA) in PBS at the concentration of 0 - 1.0 mg/mL, used as calibration standard. 
The results were obtained comparing the absorbance values of the samples with those of the BSA 
standard curve, and expressed as mg protein/mL. 
 
Table 2. Composition of Lowry reagent. 
Reagent Composition 
Lowry reagent 98% Lowry A + 1% Lowry B + 1% Lowry C 
Lowry A 2% Na2CO3 in 0,1 M NaOH 
Lowry B 1% CuSO4 in H2O 
Lowry C 2% NaKC4H4O6  2 H2O in H2O 
 
 
 
 
 
3.2. In vitro BSA glycation assay 
The in vitro BSA glycation assay was performed to evaluate the polyphenols inhibitory activity of 
protein glycation.  AGEs were determined using bovine serum albumin (BSA) as protein substrate and 
glucose, ribose or glyoxal as glicative agents. Glucose and ribose are sugars found in vivo in 
physiological conditions, while glyoxal is a highly reactive dialdehyde, a metabolite produced during 
the autoxidation of glucose and the glycation reaction (Sliman et al., 2010).  At first, we performed 
preliminary experiments to detect the ability of glucose, glyoxal and ribose to induce the AGEs 
formation on BSA. In the beginning, BSA solution was incubated with glucose, glyoxal and ribose 
solution in a black 96-well plate and kept in the dark at 37°C. The first reading with the fluorimeter 
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was performed after 24 hours, and then it was repeated every day, for seven days. The analysis of 
these first experimental results suggested the most suitable incubation time for each glycating agent. 
After the preliminary experiments, we performed the glycation assay with the selected polyphenols, 
and the phytocompounds concentrations used were 5-10-50 μM for each compound. Briefly, 100 μL 
of BSA solution was incubated with 100 μL of glucose, glyoxal or ribose solution, and with 10 μL of 
each tested compound using black 96-well plates. The final concentrations of the reagents are listed 
in the following table (table 3). The protein and sugar solutions were all prepared in PBS pH 7.4 with 
0,02% sodium azide as aseptic agent. The protein, the sugar and the prospective inhibitor were 
included in the mixture simultaneously. Aminoguanidine, a well-known inhibitor of AGEs formation, 
was used as positive control at the final concentration of 2.5 mM (Edelstein & Brownlee, 1992).  The 
plate was kept at 37°C in the dark and incubated for 5 days (glycation by ribose) or 7 days (glycation 
by glyoxal or glucose). After the incubation, fluorescence intensity of the test solutions was 
measured using a microplate reader, setting excitation wavelength at 355 nm and emission 
wavelength at 460 nm. The final results were obtained comparing the fluorescence intensity 
between the reaction mixture with the tested compound and the reaction mixture with only BSA and 
glycating agent. 
 
 
Table 3. Concentrations of the reagents 
used for the BSA glycation assay. 
Reagents [C] 
BSA 50 mg/mL 
Glucose 0.8 M 
Glyoxal 35 mM 
Ribose 0.1 M 
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3.3. HUVEC 
HUVEC are endothelial cells isolated from the umbilical vein of the cord from voluntary donors. Since 
the umbilical cord has no function in the postnatal period, it is an attractive source for human 
endothelial cells in research. These cells, at the initial passages, maintain nearly all of the features of 
native vascular endothelial cells including the expression of specific markers such as von Willebrand 
factor and endothelial specific adhesion molecule (CD31), expression of receptors for growth factors, 
cytokines, and specific signaling pathways for vascular endothelial growth factor (VEGF), fibroblast 
growth factor (FGF), transforming growth factor-β, tumor necrosis factor (TNF)-α and angiotensin II. 
Thus, HUVEC are primary cells that mimic many processes that occur also in vivo and their use has 
played a major role in the development of the field of vascular biology and has therefore become a 
classical model to study many aspects of function and disease of the human endothelium. 
 
 
 
Figure 10. Humbilical vein endothelial cells (HUVEC). 
 
 
 
HUVEC were isolated from human umbilical cord of healthy donors and used at passage 3-6 (fig. 10). 
Briefly, the serum-free PBS containing type II collagenase (10 mg/mL) was used to perfuse the 
umbilical vein in order to detach the endothelial cell layer. After dissociation, the cells were collected 
in 10 mm dishes and cultured in endothelial cell growth medium (EGM-2 BulletKit, LONZA, Verviers, 
Belgium) and maintained in a humidified atmosphere containing 5% CO2 at 37°C. The culture medium 
was replaced every 2-3 days until the first subcultivation. For sub-cultivation, cells were washed with 
PBS and detached using trypsin-EDTA 0.05% solution in PBS for 2-5 minutes at 37°C. The enzymatic 
activity of trypsin was then stopped by addition of a solution 10% FBS in PBS to the cell culture dish. 
The cell suspension was collected in a falcon and centrifuged at 1,000 rpm for 5 minutes. The 
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supernatant was discarded and the cell pellet resuspended in EGM-2 medium. Cell density of the 
suspension was measured and obtained data were used to calculate the required volume of cell 
suspension which was transferred to a new sterile culture dish. HUVEC were cultured in EBM-2 
supplemented with EGM-2 Single Quots. Cells were grown in 10 mm dish and subcultured when 
reached 80-90% confluence, using enzymatic digestion with trypsin-EDTA. Cells were cultured and 
used for the experiments at passage number 3-6. Cells treatment with compounds of interest was 
done in culture medium starvation, using EBM-2 supplemented with 1% FBS as medium. 
 
3.3.1. HUVEC cytotoxicity assay 
The cytotoxicity assay was performed to see whether the selected polyphenols could be toxic for the 
HUVEC cells at the concentrations chosen for the in vitro assays. The cytotoxicity assay was also 
performed to see a potential cytotoxic activity given by the selected compounds involved in the 
pathological condition linked with hyperglycemia and vascular disease, like glycated albumin, glyoxal 
and glucose at high concentration. The cellular viability after the treatment with the selected 
compound was determined using the MTT assay, as seen before in this chapter.  
 
 
Table 4. Concentrations of the selected compounds used 
for the MTT assay in HUVEC. 
Selected compound [C] 
Polyphenols 1-10 μM 
gHSA 200-500 μg/mL 
Glyoxal 500-5 μM 
High glucose 25 mM 
 
 
 
HUVEC cells were seeded in a 96-well plate at the density of 10’000 cells/well in EGM-2 and let grown 
for 48 hours; then cells were treated with the selected compounds in EBM-2 medium for 2-24 hours, 
following the scheme reported in the table 4. After the treatment, an aliquot of MTT solution was 
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added to each well, to reach the final concentration of 500 μg/mL. After the reduction of the MTT by 
cellular enzymes, the medium was removed and the insoluble formazan salts were solubilized with 2-
propanol/0.33% HCl (36%). The absorbance of each purple formazan solution was measured using a 
PerkinElmer 2030 VictorTMX3 setting the wavelength 520 nm. 
 
3.3.2. ROS detection in HUVEC 
The ROS formation caused by glycated albumin, glyoxal and high glucose concentration, as well as 
the effect of natural polyphenols on ROS-induced oxidative stress in HUVEC, was determined by a 
fluorimetric assay using DCFH-DA. DCFH-DA assay uses the reagent 2’, 7’-dichlorofluorescein 
diacetate (DCFH-DA), a fluorogenic dye that allow to measure hydroxyl, peroxyl and other reactive 
oxygen species (ROS) within the cell. After diffusion into the cell, DCFH-DA is deacetylated by cellular 
esterases to a non-fluorescent compound, which is later oxidized by ROS into 2’, 7’-
dichlorofluorescein (DCF). DCF is a highly fluorescent compound which can be detected by 
fluorescence spectroscopy with maximum excitation and emission spectra of 485 nm and 538 nm. 
The fluorescence intensity of DCF is proportional to the ROS formed within the cells (H. Wang & 
Joseph, 1999).  
 
 
Table 5. Concentrations of the selected compounds chosen 
for the ROS detection assay on HUVEC cells. 
Selected compound [C] 
Polyphenols 1-5 μM 
gHSA 200-500 μg/mL 
Glyoxal 500-5 μM 
High glucose 25 mM 
 
 
 
 
Following the experimental protocol, HUVEC cells were seeded in a 96-well plate at the density of 
10’000 cells/well in EGM-2 and let grown for 48 hours; then cells were treated with the selected 
 - 39 - 
 
compounds in starvation medium for 2-24 hours, following the scheme reported in the table 5. In 
order to evaluate the polyphenols activity, cells were pre-incubated for 2 hours with each 
phytoconstituent (1-5 μM), and then treated with high glucose for 24 h.  HUVEC were then incubated 
with DCFH-DA 25 μM for 30 minutes. The fluorescence intensity was measured at 485 nm excitation 
and 538 nm emission wavelengths using a PerkinElmer Victor TM X3 microplate reader (Waltham, MA, 
USA).  
 
 
3.4. HUVECtert  
In vitro, normal somatic cells undergo a non-dividing state termed cellular replicative senescence. 
The erosion of telomeres, due to the inactivity of telomerase, a reverse transcriptase which 
synthesizes telomeric DNA, has been suggested to contribute to cellular replicative senescence (Levy, 
Allsopp, Futcher, Greider, & Harley, 1992). Like most human somatic cells, HUVEC undergo 
replicative senescence in vitro after a finite number of divisions, which can vary between 40 and 60 
population doublings. In order to save time and resources in the research, it is necessary to increase 
the lifespan of endothelial cells in vitro. A way to bypass senescence has been achieved by ectopic 
expression of the human telomerase reverse transcriptase (hTERT) gene. HUVECtert are HUVEC 
immortalized by infection with lentiviral particles encoding the hTERT (fig. 11), (Schiller, Szekeres, 
Binder, Stockinger, & Leksa, 2009). 
 
 
 
Figure 11. HUVECtert cells. 
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The experiments performed using HUVECtert cells were done during the research exchange project 
in Vienna, at the “Molecular Target group” of the Department of Pharmacognosy, under the 
supervision of Ass. Prof. Dr. E. Heiss. HUVECtert were cultured in Endothelial Basal Medium (EBM™) 
supplemented with EGM™ SingleQuots™. Cells were grown in 10 mm dish and subcultured when 
reached 80-90% confluence, using enzymatic digestion with trypsin-EDTA. The treatment with 
compounds of interest was done in starvation, using EBM/1% FBS as medium. 
 
3.4.1. VCAM-1 expression in HUVECtert 
VCAM-1 (vascular cell adhesion molecule 1) is an immunoglobulin-like adhesion molecule expressed 
on activated endothelial cells.  Endothelial cells up-regulate the expression of the adhesion molecules 
in response to NF-kB signaling activation, for the recruitment of leukocytes as one of the major 
events in the development of inflammation (Cook-Mills, Marchese, & Abdala-Valencia, 2011). VCAM-
1 binds to α4β1 integrin, which is constitutively expressed on lymphocytes, monocytes, and 
eosinophils. VCAM-1 mediates leukocyte-endothelial cell adhesion and signal transduction and may 
play a role in the development of atherosclerosis and other inflammatory diseases. Thus, VCAM-1 
signaling is a target for intervention by pharmacological agents and by antioxidants during 
inflammatory diseases. 
In this work, flowcytometry was used to detect the pro-inflammatory cell adhesion proteins VCAM-1 
in HUVECtert. Briefly, cells were seeded into pre-coated (0.1 % gelatin in PBS incubated 10-15 
minutes at 37°C) 12-well-plates in 2 ml of HUVEC culture medium and grown overnight; then, cells 
were pre-incubated with compounds of interest (5-10 μM) or solvent vehicle as control for 30 
minutes, and then treated with TNFα 20 ng/mL. After the incubation at 37°C, 5% CO2 for 18-20 hours, 
cells were washed with PBS and detached using trypsin. Cells suspension was transferred to FACS-
vials and centrifuged for 4 minutes at 150 rpm; then supernatant was discarded and after two 
washing with PBS/2%BSA, 35 μL of anti-FITC-VCAM-1 antibody were added into each tube, which was 
incubated on ice in the dark for 60 minutes. After the incubation, 1 mL of PBS/BSA was added, and 
after washing two times with PBS/BSA, the pelleted cells were resuspended in 250 μL of PBS/BSA and 
analyzed immediately using a flowcytometer. 
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4. RESULTS 
 
4.1. Cellular uptake in HT-29 cells  
Information about natural compounds ability to cross biological membranes is of great interest and 
importance to deepen the study about their potential in vivo biological activities. The cellular uptake 
assay was performed to see in what extent the tested phytocompounds were able to cross the 
intestinal HT-29 cell membrane and be found in the cytosol. HT-29 cells were treated with the 5 μM 
polyphenols solution and the chromatographic analysis was performed using HPLC-DAD apparatus.  
At first, the chromatographic analysis related to the intracellular content and the extracellular 
solution were performed, and the chromatograms were recorded at the wavelength range of 200-
400 nm, using a PDA detector. Successively, the appropriate wavelength applicable for the analysis of 
each tested polyphenols was selected, relying on the UV spectrum and λ max of the standard 
solution of the tested compound (tab. 6). We proceeded to the peak identification, comparing the 
chromatogram relative to the intracellular and the extracellular contents with the chromatogram of 
the analytical standard, to detect whether the compounds were able to cross the cellular membrane. 
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Figure 12. Intracellular content of polyphenols measured in HT-29 cells after 3 h treatment; the 
concentration is expressed as nmol of compound per mg of cellular protein (A). The panel B show the 
results relative to the concentration of each polyphenols measured in the extracellular medium after 3 h 
treatment of HT-29 cells; results are expressed as μM concentration. M = metabolite; ND = not detected. 
Each value represents mean ± SD of at least three experiments. 
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Table 6. UV spectra of polyphenols and selected λ max used to detect each compound. 
Compound UV spectrum λ max 
Baicalein  
 
276 nm 
Eupatorin  
 
345 nm 
Galangin  
 
358 nm 
Magnolol  
 
290 nm 
Myricetin  
 
376 nm 
Oleuropein  
 
250 nm 
Silybin 
 
 
288 nm 
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The study of the extracellular and intracellular solutions was some time a difficult task because of the 
presence of several and different peaks in the chromatograms, with different retention times and UV 
spectra from the reference compound. The experimental conditions applied in the assay leaded to 
the presence of compounds with different retention time and UV absorption than the tested 
polyphenol, suggesting the presence of metabolites of the original compound. Data from literature 
helped the peak identification, where possible, with the comparison of the λ max and UV spectra. 
In the table 7 are summarized the data from the polyphenols cellular uptake assay. The intracellular 
content of the polyphenols is express as nmol compound/mg cellular protein, whereas the 
extracellular concentration is express as μM. 
In general, the results from the cellular uptake showed that the flavonoid eupatorin and the 
neolignan magnolol are able to cross the HT-29 cell membranes, considering that they are found in 
the cytosol after 3 hours of incubation. Moreover, we observed that baicalein and galangin not only 
were able to pass through the cell membrane, but also underwent biotransformation process. 
Indeed, peaks which did not correspond to the original compound were found in the intra- and 
extracellular solution. Conversely, oleuropein and silybin seemed not able to be taken up by the HT-
29 cells, and they were found in the native form only in the extracellular solution (fig. 12). 
In particular, as seen in figure 18, baicalein was not detected in the extracellular medium after 3 
hours of incubation. Baicalein was taken up in the cells during the assay, and moreover it was 
transformed in different compounds not identifiable with baicalein itself. The differences in the 
retention times and the UV spectra of the different peaks suggested the presence of metabolites of 
the flavonoid; data from literature suggest the intestinal metabolism of baicalein into glucuronidated 
forms, especially in C-7 (fig. 13).  
 
         
Figure 13. Molecular structure of baicalein (on the left), and its conjugated 
form baicalein-7-glucuronide (on the right). From: Zhang et al., 2007. 
 
5 
6 
7 
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The chromatographic analysis with baicalein-7-glucuronide standard solution was performed, and 
the comparison between the chromatogram from the uptake assay and the chromatogram of the 
standard of baicalein-7-glucuronide validated the presence of this metabolite in the intracellular 
compartment (fig. 14). The retention time and the UV spectrum of baicalein-7-glucuronide standard 
and the ones from the unknown compound were overlapping; so the major metabolite has been 
identified as baicalein-7-glucuronide (Rt 6.53 min), a conjugated form of baicalein, which was 
quantified equal to 0,60 ± 0,20 nmol/mgprot. 
The flavonoid eupatorin was able to permeate the intestinal HT-29 cells; as seen in figure 15 the peak 
corresponding to the standard eupatorin is present in both the chromatograms (intra- and 
extracellular compartments), and the UV spectrum and the retention time of the peaks were 
comparable with the analytical standard of eupatorin. The amount of eupatorin detected in the cells 
was 0.3 ± 0.02 nmol/mgprot. The experimental conditions chosen for the assay allowed the partial 
internalization of the flavonoid, thus, after 3 hours of incubation, eupatorin was quantified in the 
extracellular solution at the concentration of 1.87 ± 0.3 μM. No other peaks were found in either the 
intra- or extracellular solutions, so in these conditions no metabolism reactions occurred.  
 
 
Table 7. Cellular uptake in HT-29 cells: intracellular and extracellular content detected in HT-29 cells 
after 3 h treatment with each polyphenols at the concentration of 5 μM. 
Treatment  
[5 μM] 
Intracellular 
content 
[C] 
nmol/mg protein 
Extracellular 
content 
[C] 
μM 
Baicalein Bai-7-glucuronide 0.60 ± 0.20 Bai-7-glucuronide 0.91 ± 0.24 
Eupatorin Eupatorin 0.30 ± 0.02 Eupatorin 1.87 ± 0.30 
Galangin Galangin 0.12 ± 0.02 - - 
Magnolol Magnolol 0.25 ± 0.02 Magnolol 2.71 ± 0.15 
Myricetin - - - - 
Oleuropein - - Oleuropein 4.81 ± 0.54 
Silybin - - Silybin 2.81 ± 0.10 
-: not detected. 
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Figure 14. The HPLC chromatographic analysis of baicalein content in HT-29 cells.  In the figure, the 
chromatograms relative to the intracellular content, extracellular content and analytical standard are reported. 
The panels on the right show the UV spectra of the peaks revealed during the chromatographic analysis. The 
peak 1 has been identified as baicalein-7-glucuronide. Intracellular and extracellular flavonoids levels are 
compared with that of baicalein standard (peak 4, Rt 6.53 min) and baicalein-7-glucuronide standard (peak 1, 
Rt 3.83 min). 
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The extracellular medium from galangin treated cells yielded several peaks, as shown in figure 16; 
the peak at 6.46 min relative to galangin was not detected, but new peaks were detected at Rt 4.98 
and 5.83. The UV spectra of the two peaks are reported in figure 16, these were similar to galangin 
UV spectrum, suggesting the presence of its metabolites. Furthermore, the intracellular content of 
galangin treated cells showed the presence of several peaks (Rt 5.83, 6.46, 7.40 min), and the one at 
Rt 6.46 min, with absorbance maxima at 265 and 358 nm, corresponded with the galangin peak in 
the analytical standard chromatogram. The additional peaks had UV spectra similar to galangin, 
suggesting the presence of possible galangin metabolites.  
The results about cellular uptake of magnolol are reported in figure 17, which shows the 
chromatographic analysis of intra- and extracellular solutions. In both the chromatograms was 
detected a peak at 9.98 and 10.08 minutes, nearly the same retention time of magnolol standard (Rt 
10.05 min). The UV spectra of the two peaks confirmed the presence of magnolol inside and outside 
the cells. The intracellular content of magnolol was quantified equal to 0.25 ± 0.02 nmol/mgprot, and 
the extracellular concentration was 2.71 ± 0.15 μM. 
The chromatograms relative to the analysis of the cellular uptake of myricetin are reported in figure 
18. In both chromatograms of intra- and extracellular contents, recorded at 376 nm, the peak 
relative to myricetin (Rt 4.25 min) was not detected. The chromatograms were analyzed at all the 
wavelengths recorded from 200 to 400 nm, but no peaks were revealed. This could be due to 
changes in myricetin structure induced by oxidation reaction, leading to the formation of not 
detectable compounds. 
The data from the uptake assay of oleuropein showed that the compound was not able, in the 
experimental conditions, to cross cellular membranes, and the peak relative to oleuropein was found 
only in the chromatogram of extracellular solution (fig. 19). The peak was identified as oleuropein by 
comparison with the retention time and UV spectrum of the analytical standard. In the intracellular 
content chromatogram no peaks were found at all the wavelengths analysed. The determination of 
oleuropein concentration in the extracellular solution was performed using the standard curve, and 
the result showed that oleuropein was present in the extracellular compartment at the 
concentration of 4.81 ± 0.54 μM. 
The extracellular medium from silybin treated cells yielded only two peaks (fig. 20). The comparison 
with retention time and UV spectrum of the analytical standard confirm the identification of the 
peaks as silybin A and B. The concentration of silybin found in the extracellular compartment was 
equal to 2.81 ± 0.10 μM. No peaks related to silybin were found in the intracellular compartment. 
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Figure 15. HPLC chromatographic analysis of eupatorin content in HT-29 cells.  In the figure, the 
chromatograms relative to the intracellular content, extracellular content and analytical standard are reported. 
The panels on the right show the UV spectra of the peaks revealed during the chromatographic analysis. The 
peak 1 has been identified as eupatorin. Intracellular and extracellular flavonoid levels are compared with that 
of eupatorin standard (peak 1, Rt 6.32 min). 
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Figure 16. HPLC chromatographic analysis of galangin content in HT-29 cells.  In the figure, the chromatograms 
relative to the intracellular content, extracellular content and analytical standard are reported. The panels on 
the right show the UV spectra of the peaks revealed during the chromatographic analysis. The peak 2 has been 
identified as galangin. Intracellular and extracellular flavonoid levels are compared with that of galangin 
standard (peak 2, Rt 6.46 min). 
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Figure 17. HPLC chromatographic analysis of magnolol content in HT-29 cells.  In the figure, the chromatograms 
relative to the intracellular content, extracellular content and analytical standard are reported. The panels on 
the right show the UV spectra of the peaks revealed during the chromatographic analysis. The peak 1 has been 
identified as magnolol. Intracellular and extracellular polyphenol levels are compared with that of magnolol 
standard (peak 1, Rt 10.05 min). 
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Figure 18. HPLC chromatographic analysis of myricetin content in HT-29 cells.  In the figure, the chromatograms 
relative to the intracellular content, extracellular content and analytical standard are reported. The panels on 
the right show the UV spectrum of the peak revealed during the chromatographic analysis. The peak 1 
represent the standard myricetin (peak 1, Rt 4.25 min). 
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Figure 19. HPLC chromatographic analysis of oleuropein content in HT-29 cells.  In the figure, the 
chromatograms relative to the intracellular content, extracellular content and analytical standard are reported. 
The panels on the right show the UV spectra of the peaks revealed during the chromatographic analysis. The 
peak 1 has been identified as oleuropein. Extracellular polyphenol level is compared with that of oleuropein 
standard (peak 1, Rt 5.08 min). 
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Figure 20. HPLC chromatographic analysis of silybin content in HT-29 cells.  In the figure, the chromatograms 
relative to the intracellular content, extracellular content and analytical standard are reported. The panels on 
the right show the UV spectra of the peaks revealed during the chromatographic analysis. The peaks 1 and 2 
have been identified as silybin (the two isomer of silybin A and B). Extracellular polyphenol level are compared 
with that of silybin standard (peak 1, Rt 5.48 min; peak 2, Rt 5.60 min). 
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4.2. In vitro BSA glycation assay 
AGEs are the final products of the non-enzymatic reaction between reducing sugar and amino groups 
in protein, lipoproteins and nucleic acids. AGEs can play a physio-pathological role through the 
binding of specific receptors, initiating a signal cascade with pro-oxidant and pro-inflammatory 
effects. This is the reason why they are well known agents related to hyperglycemia, which worsen 
the vascular damage induced by atherosclerosis. Considering all the dangerous effects of the 
glycation process, a strategy for the prevention of the AGEs formation could be promising and helpful 
in reducing the negative consequences.  
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Figure 21. The effects of glucose (G), glyoxal (GO) and ribose (R) on the AGEs formation on BSA. BSA was 
incubated with glucose 0,8 M, glyoxal 35 mM and ribose 0,1 M, then the fluorescence intensity of the 
reaction mixture was measured setting λ excitation 355 nm and λ emission 460 nm. (A) Time-dependent 
evaluation of AGEs formation. (B) Evaluation of AGEs formation measuring the fluorescence intensity after 
5 days of incubation of BSA with ribose, and after 7 days of incubation with glucose or glyoxal. 
 
 
 
The preliminary experiments allowed us to investigate the ability of glucose, glyoxal and ribose as 
inducer of AGEs formation in BSA. A time-course assay was performed, and the results showed that 
glucose, glyoxal and ribose have a different ability of inducing the AGEs formation. Ribose was the 
fastest in vitro glycation inducer, as seen in figure 21, with a maximum of fluorescent AGEs formation 
after five days of incubation with BSA. Glyoxal showed a good glycating activity after seven days of 
incubation, whereas glucose needed more time to complete the glycation reaction, reaching a lower 
A B 
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level of fluorescent AGEs after seven days. These results were compared with the ones from the 
literature, thus, the end-point chosen for the fluorimetric measures were five days for ribose and 
seven days for glyoxal and glucose. The graph in figure 21 shows the fluorescence intensity of AGEs 
formed during the assay and measured after five or seven days. It seemed clear that ribose is not 
only the fastest glycation inducer but also the strongest, with the highest value of fluorescence 
intensity. Glucose showed a little but significant increase in fluorescence intensity, compared to the 
not treated BSA. 
The following experiments were conducted to evaluate the inhibitory activity of the polyphenols on 
the AGEs formation. 
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Figure 22. Antiglycative activity of the selected polyphenols expressed as inhibition of AGEs 
formation induced by glucose (G). Aminoguanidine (AG) was used as positive control. Each 
value represents mean ± SD of at least three experiments, * p < 0.05 vs BSA treated with 
glucose alone (ctrl G). 
 
 
 
The figure 22 shows the results of the inhibitory activity of the polyphenols on the glycation induced 
by glucose. All the tested polyphenols showed antiglycative activity at the concentration of 50 μM, 
with different percentage of inhibition. Interestingly, baicalein, eupatorin, myricetin and silybin also 
 - 57 - 
 
inhibited the AGEs formation at the concentration of 10 μM, whereas baicalein was the only 
compound that exerted the antiglycative activity at 5 μM.  
In the BSA-glyoxal assay (fig. 23), galangin and magnolol at the 50 μM concentration showed the 
highest activity. Together with baicalein and eupatorin, they showed inhibitory activity also at the 
concentration of 10 μM. Moreover, magnolol and eupatorin 5 μM were able to inhibit the AGEs 
formation induced by glyoxal.  
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Figure 23. Antiglycative activity of selected polyphenols expressed as inhibition of AGEs 
formation induced by glyoxal (GO). Aminoguanidine (AG) was used as positive control. Each 
value represents mean ± SD of at least three experiments, * p < 0.05 vs BSA treated with 
glyoxal alone (ctrl GO). 
 
 
 
Baicalein, galangin and magnolol showed good antiglycative activity in the BSA-ribose assay, too, 
with a particular and significant inhibition of AGEs formation at 10-50 μM (fig. 24). Although silybin 
exerted a significant activity against the glycation induced by glucose, in the BSA-glyoxal and BSA-
ribose assay silybin showed the inhibitory activity only at 50 μM. A very weak antiglycative activity 
was shown by oleuropein in all the tested conditions, except for oleuropein 50 μM in the BSA-glucose 
assay. Analysing the results obtained so far, the polyphenols with the highest activity in preventing 
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the AGEs formation were baicalein, eupatorin and magnolol, with elevated activities in all three 
glycation conditions and significant activities also at the lower concentration of 5 μM. 
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Figure 24. Antiglycative activity of selected polyphenols expressed as inhibition of AGEs 
formation induced by ribose. Aminoguanidine (AG) was used as positive control. Each value 
represents mean ± SD of at least three experiments, * p < 0.05 vs BSA treated with ribose 
alone (ctrl R). 
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4.3. VCAM-1 expression in HUVECtert 
Endothelial cells upregulate the expression of the adhesion molecules in response to inflammation 
signaling, for the recruitment of leukocytes as one of the major events in the development of 
inflammatory diseases. To see whether the compounds were able to induce or reduce the expression 
of the adhesion molecules, the flowcytometric analysis on VCAM-1 was performed (fig. 25).  
 
 
 
 
 
 
Figure 25. Flowcytometric analysis of VCAM-1 expression on HUVECtert. The cells were incubated 
for 30 minutes with the tested compounds (or vehicle control), and then treated with TNFα. CDDO 
(2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid) was used as positive control (100 nM). The 
fluorescence of the anti-FITC-VCAM-1 antibody on the selected cells was measured and all the 
results were compared to the TNFα-treated cells. The panels shown in the figures are relative to 
the flowctometric analysis of HUVECtert treated with TNFα, and of cells pre-incubated with CDDO, 
eupatorin 5 μM and eupatorin 10 μM. 
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Figure 26. Relative VCAM-1 expression in HUVECtert evaluated using 
flowcytometry. Glycated albumin (gHSA) was not able to induce 
VCAM-1 expression compared to the not-treated cells (ctrl). TNFα 
was used as stimulus, and CDDO as positive control. The evaluation 
of flavonoids ability to inhibit TNFα-induced VCAM-1 expression 
showed that baicalein (5-10 μM) had no effect in inhibiting the TNFα 
activity, whereas eupatorin (5-10 μM) displayed a significant activity. 
Each value represents mean ± SD of at least three experiments, * p < 
0.05 vs TNFα treated cells (TNFα). 
 
 
 
The first experiments evaluated if glycated albumin was able to induce an inflammatory event in the 
endothelial HUVECtert cells, as the VCAM-1 expression; moreover, the aim was to examine if the 
flavonoid compounds baicalein and eupatorin were able to reduce the VCAM-1 expression induced 
by TNFα. The concentrations used in this assay were 200 μg/mL for gHSA, and 5 and 10 μM for the 
flavonoids. CDDO (2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid) was used as positive control at the 
concentration of 100 nM. The obtained results were compared to the TNFα-treated cells, and they 
were expressed as relative percentage of VCAM-1 expression. In figure 26 it can be seen that 
HUVECtert did not increase the expression of adhesion molecules after the treatment with glycated 
albumin. Thus, gHSA was not able to induce the inflammatory event like VCAM-1 expression. 
Moreover, the flavonoid baicalein at both concentrations tested in the assay did not counteract the 
effect of TNFα in inducing VCAM-1 expression, whereas eupatorin at 5 and 10 μM exerted a 
significant anti-inflammatory activity, showing a VCAM-1 expression inhibition of 23.7 ± 0.10% and 
51.6 ± 0.07%. 
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4.4. HUVEC cytotoxicity assay 
The MTT viability assay was performed to see a potential cytotoxic activity given by the selected 
compounds involved in the pathological condition linked with hyperglycemia and vascular disease, 
like glycated albumin, glyoxal and glucose at high concentration. 
At first, the effect of gHSA on the viability of HUVEC was evaluated. The results, reported in figure 27, 
showed that glycated albumin was not cytotoxic for HUVEC after 24 hours of treatment, but it 
seemed to have a proliferative effect, which was significant for the concentration 200 and 500 
μg/mL. The highest concentration tested of gHSA determined an increase in cells viability of about 
158 %. 
 
g ly c a te d -H S A  2 4 h
V
ia
b
le
 c
e
ll
s
 (
%
)
c
tr
l
g
H
S
A
 2
0
0
g
H
S
A
 5
0
0
B
S
A
 2
0
0
B
S
A
 5
0
0
0
5 0
1 0 0
1 5 0
2 0 0
2 5 0
 g /m L
*
*
 
Figure 27. Effect of glycated albumin (gHSA) on the 
viability of HUVEC, assessed using the MTT assay. The 
concentrations chosen for gHSA were 200-500 μg/mL. 
Bovine serum albumin (BSA), not glycated, was used as 
protein control. Each value represents mean ± SD of at 
least three experiments, * p < 0.05 vs not treated cells 
(ctrl). 
 
 
The cytotoxic effect of glyoxal on HUVEC was performed choosing a concentration range of 0.2-5.0 
mM. The MTT assay was performed after glyoxal treatment of 2 and 24 hours. The results, reported 
in figure 28, showed low cytotoxic activity of glyoxal after 2 hours treatment; at the highest 
concentration tested glyoxal reduced the cells viability to 64.3%. After 24 hours treatment, glyoxal 
displayed a stronger effect on HUVEC, reducing the cells viability starting from the 0.5 mM 
concentration. After 24 hours treatment with glyoxal 5 mM the HUVEC viability was reduced to 5.9%. 
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Figure 28. Cytotoxic effect of glyoxal (GO) on HUVEC expressed as percentage of viable cells. Cells 
were treated with different concentrations of glyoxal for 2 h (A) or 24 h (B). Each value represents 
mean ± SD of at least three experiments, * p < 0.05 vs not treated cells (ctrl). 
 
 
It was further detected the activity on HUVEC of glucose at high concentration (hGLU; 25 mM), to see 
whether it could have a toxic effect on endothelial cells after 24 hours treatment. The results, 
reported in figure 29, showed that high glucose did not influence the HUVEC viability in the 
conditions chosen for the assay. 
In summary, glycated albumin had not cytotoxic activity on HUVEC, conversely it showed a 
proliferative effect on endothelial cells. It was also observed that glyoxal determined a reduction of 
the cells viability especially after 24 hours, whereas high glucose did not impaired cellular viability 
after 24 h treatment. 
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Figure 29. The effect of glucose at high concentration 
(hGLU; 25 mM) on the viability of HUVEC. Each value 
represents mean ± SD of at least three experiments, * p 
< 0.05 vs not treated cells (ctrl). 
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4.5. ROS detection in HUVEC 
Oxidative stress is described as the imbalance between the ROS production and the antioxidant 
defenses. The excess of ROS production could have negative consequences in the organism and is 
associated with hyperglycemic condition, diabetes and atherosclerosis. Several factors related to 
hyperglycemia and diabetes could promote oxidative stress and ROS formation, therefore in this 
research work the activity of glycated albumin, glyoxal and high glucose were evaluated using the 
DCFH-DA assay.  
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Figure 30. The effects of glycated albumin (gHSA), glyoxal (GO) 
and high glucose (hGLU) on ROS formation in HUVEC, 
measured using DCFH-DA. Cells were treated with the selected 
compounds and ROS formation was measured within 2 h. Each 
value represents mean ± SD of at least three experiments, * p 
< 0.05 vs not treated cells (ctrl). 
 
 
At first, we evaluated potential effects of the selected compounds in inducing ROS formation in 
HUVEC after 2 hours treatment (fig. 30). Glycated albumin, as well as glyoxal, was not able to induce 
ROS formation in the cells, at the concentrations chosen for the assay. Instead, the treatment of 2 
hours with glucose at high concentration determined an increase of ROS in HUVEC, with a rise of 
about 134%.  
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The following step has been the evaluation of the activity of glyoxal and high glucose on the ROS 
formation after a longer treatment. After 24 hours of incubation, high glucose was able to increase 
ROS production in HUVEC cells of 134.9 ± 9.9 %, whereas glyoxal did not increase ROS formation (fig. 
31).  
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Figure 31. Oxidative stress in HUVEC: ROS formed after 
treatment with glyoxal 0.5 mM (GO) and high glucose 
(hGLU) for 24 h. Each value represents mean ± SD of at 
least three experiments, * p < 0.05 vs not treated cells 
(ctrl). 
 
 
 
After the evaluation of the activity of glycated albumin, glyoxal and high glucose on ROS formation in 
HUVEC, it was clear that high glucose was the only compound able to induce oxidative stress in the 
experimental conditions. 
To prevent and counteract ROS formation in endothelial cells assumes an important role in the 
treatment of oxidative stress-related pathologies. Natural products from medicinal plants could be 
good candidate as agents that protect ROS-induced damage, therefore the antioxidant activity of the 
polyphenols baicalein, eupatorin and galangin was evaluated using the DCFH-DA assay. 
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Figure 32. Antioxidant effect of selected polyphenols baicalein, 
eupatorin and galangin expressed as percentage inhibition of 
ROS formation in HUVEC after 2 hours treatment. Not-treated 
cells were used as control. Each value represents mean ± SD of 
at least three experiments, * p < 0.05 vs control (ctrl). 
 
 
 
At first, we evaluated the activity of the selected polyphenols in reducing ROS production in HUVEC 
in basal condition, without any oxidative stressor. The cells were treated for 2 hours with each 
natural compound, and then DCFH-DA was added. Fluorescence of reduced DCF was measured and 
the results are reported in figure 32. In basal condition, baicalein and galangin at 1 and 5 μM were 
able to significantly reduce the ROS formation in HUVEC, whereas eupatorin did not displayed any 
antioxidant activity at both concentrations tested. The ROS formation in HUVEC after the treatment 
with baicalein 1 and 5 μM was inhibited of 18.3 ± 6.1 and 32.0 ± 5.7 %. Also galangin 1 and 5 μM 
displayed antioxidant activity, reducing ROS formation of 19.5 ± 4.6 % and 39.0 ± 5.8 % (fig. 32).  
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Figure 33. Antioxidant activity of baicalein, eupatorin and galangin 
expressed as percentage of ROS formation in HUVEC after 24 hours 
treatment with high glucose (hGLU). Each value represents mean ± 
SD of at least three experiments, * p < 0.05 vs HUVEC treated with 
high glucose (hGLU). 
 
 
 
Afterwards, we evaluated the antioxidant activity of the polyphenols after stimulation of HUVEC with 
high glucose, chosen as oxidative stressor (fig. 33). Cells were pre-treated with each compound at the 
concentrations of 1-5 μM, and then cells were treated with high glucose (25 mM) for 24 hours. The 
pro-oxidant effect of high glucose on the ROS formation was referred as 100% of ROS production. All 
the polyphenols seemed to counteract the ROS formation induced by high glucose treatment, except 
for eupatorin at the concentration of 1 μM. The ROS formation in HUVEC after pre-treatment with 
baicalein 1 and 5 μM was 84.2 ± 7.2% and 63.7 ± 6.6% , and after pre-treatment with galangin 1 and 
5 μM was 77.2 ± 11% and 65.4 ± 3.9%. Eupatorin showed an antioxidant activity at the concentration 
of 5 μM, reducing the ROS formation to 70.3 ± 4.8%.  
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5. DISCUSSION 
 
5.1. Cellular uptake in HT-29 cells  
Medicinal plants and natural products still represent important sources for the identification of new 
pharmacological leads today. Several natural compounds have been shown to affect vascular and 
metabolic disorders, via different mechanisms, such as anti-inflammatory activity, changes of blood 
lipid profiles, improvement of insulin sensitivity, or normalization of blood glucose levels (Lee et al., 
2006; Pan et al., 2010; Yugarani et al., 1992). The polyphenols have aroused great scientific interest, 
since their beneficial effects are attributed to several activities including antioxidant capacity. It is 
well known that the phenolic compounds can act as metal chelators and radical scavengers, and 
might also trigger changes in cells and in the signaling pathways, as by preventing the LDL oxidation, 
platelet aggregation, and ROS generation. It has become clear that the health effects of polyphenols 
greatly depend on their permeability and bioavailability, namely the bioactive forms in vivo. The 
polyphenols bioactive form is not necessarily the natural chemical structure, for example their 
aglycones or their glycosides, but instead their conjugates and metabolites, arising from their 
metabolism during the absorption phase. There are now strong evidences for the extensive phase-I 
deglycosylation and phase-II metabolism of the aglycones such as quercetin, hesperidin and 
epicatechin to glucuronides, sulphates and O-methylated forms during transfer across the small 
intestine and again in the liver (Spencer et al., 2004). The cellular effects of polyphenols (or their 
metabolites) will ultimately depend on the extent to which they associate with cells, either by 
interaction at the membrane and uptake into the cytosol. Circulating glucuronides, sulphates and 
methylated forms of polyphenols are believed to be the most present forms in vivo and the most 
likely to exert bioactivity. Thus, information regarding uptake of polyphenols and their modification 
into metabolites has become increasingly important to understand their potential role as modulators 
of intracellular signaling crucial for cellular function. The informations about permeability, 
metabolism and bioavailability of natural compounds are important even because they represent 
essential and usefull parameters that have to be considered in the process of drug formulation.  
It is well established that the gastrointestinal tract plays a significant role in the metabolism of 
polyphenols before entering the hepatic and systemic circulation. Therefore, in order to evaluate the 
polyphenols ability to cross the intestinal cells membrane and permeate into the cells, in the present 
research work human colorectal carcinoma HT-29 cells were used as reference model of intestinal 
barrier (Collett et al., 1996). It should be noted that the assessment of polyphenols cellular uptake 
using in vitro cell culture models may not fully reflect uptake in vivo. Despite this, the polyphenols 
 - 68 - 
 
cellular uptake studies still provide important information on which natural compounds or their 
metabolites are most able to cross cellular membrane and permeate into cells. 
Baicalein is a bioactive flavone isolated from Scutellaria radix, a traditional Chinese medicinal herb 
derived from Scutellaria baicalensis G. Despite the variety of beneficial effect of baicalein, 
investigations on its metabolism are not complete. Studies from literature have demonstrated that 
there is an extensive first-pass metabolism of baicalein and that conjugated metabolites were 
predominant in systemic circulation after oral administration in rats (Zhang et al., 2011). 
Pharmacokinetic studies in rats discovered that baicalein-glucuronide is the major metabolite found 
in circulation after oral administration. To fully understand the mechanism behind the metabolism of 
baicalein, several studies were conducted on cultured cells and intestinal and liver microsome from 
humans and rats (Zhang et al., 2007). Caco-2 (human epithelial colorectal adenocarcinoma) cells have 
been used as model for intestinal absorption of drugs, and results indicated the same first-pass 
metabolism of baicalein observed in rats, showing that over 90% of baicalein was rapidly converted 
to baicalein-glucuronide (Zhang et al., 2005). The results from the present research showed that 
baicalein in cultured HT-29 cells undergoes intestinal-like metabolism, since the HPLC analysis of the 
intracellular content revealed three different peaks, apart from baicalein. The major peak has been 
identified as baicalein-glucuronide, confirming that phase-II intestinal metabolism of baicalein 
occurs, also in HT-29 cultured cells.  The other two peaks could be related to other baicalein 
metabolites, and, comparing the data from literature, they may be associated with baicalein-
glucuronide isomer and baicalein-sulphate (Zhang et al., 2007). Apart from cellular uptake, several 
peaks were revealed also in the extracellular compartment, suggesting a potential cellular transport 
of baicalein-glucuronide. Carrier-mediated transport is a cellular system that mediates the flux of 
drugs and phase-II conjugated metabolites through cellular membranes, and this system could play a 
role during the intestinal absorption of baicalein. Further studies are needed to fully elucidate the 
fate of baicalein in the human organism; however, part of the pharmacological effects observed for 
baicalein may be due to the biological activity of baicalein-glucuronide.  
Eupatorin is a polymethoxylated flavones isolated from Orthosiphon stamineus B., a medicinal herb 
used in folk medicine in South East Asia for treatment of various disorders. It is known that the main 
reason for the low oral bioavailability of the flavonoids is the extensive conjugation of the free 
hydroxyl groups (Wen & Walle, 2006). The exclusive feature in the chemical structure of eupatorin is 
the polymethoxylation of the hydroxyl groups. The characteristics of polymethoxylated flavonoids 
are their multiple methoxyl groups, instead of free hydroxyl groups, and the higher lipophilic 
properties. These features result in increased metabolic stability and membrane transport in the 
intestine and in the liver, improving the oral bioavailability (Walle et al., 2007). The bioavailability of 
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different formulations containing polymethoxylated flavonoids was evaluated by Evans and 
colleagues, and the results show that the serum samples from healthy subjects after oral 
administration demonstrate detectable amounts of unmodified compounds (Evans et al., 2012). The 
results from the present research confirmed that the presence of multiple methoxyl substituents in 
the chemical structure protected eupatorin against metabolism conjugation. Unlike other flavonoids 
studied in this research, as baicalein or galangin, the only peaks revealed in the HPLC analysis of the 
intra- and extracellular contents of HT-29 cells after the treatment with eupatorin, were those 
relative to eupatorin. The compound was able to permeate into the cells and no metabolism reaction 
occurred during the time frame of the uptake experiment, since eupatorin was present in the native 
form both inside and outside the cells. Further studies are needed to deepen the research on the 
bioavailability of eupatorin and to find the actual amount of the natural compound achievable in 
vivo.   
Galangin is a flavonol compound isolated from the rhizome of Alpinia officinarum H., a traditional 
herb medicine used for rheumatic pains and arthritis. The metabolism of flavonols, such as quercetin, 
has been largely studied in cultured cells, rat intestine and liver cells (Walle, 2004). It is reported an 
extensive pre-systemic metabolism by glucuronidation, sulfation and methylation in the intestine and 
in the liver, therefore accurate and complete pharmacokinetic information on flavonols is useful to 
understand their bioactivity and the in vivo circulating form, as well as the actual compound which 
reach the target sites in the organism. Overall, in vivo pharmacological studies have confirmed that 
galangin could have lots of beneficial effects (Chen et al., 2015). However, these effects could be 
attributed to galangin metabolites, thus it is important to study the effect of intestinal cells to this 
natural compound. In vitro studies have revealed that galangin can be oxidized to kaempferol, but 
galangin mainly undergoes glucuronidation and sulfation in human hepatocytes (Otake et al., 2002). 
In vivo studies in rat plasma suggest that galangin is preferentially metabolized into glucuronide and 
sulphate, rather that by oxidation (Chen et al., 2015). The results from the present research showed 
that galangin, in cultured HT-29 cells, undergoes metabolism. The HPLC analysis of the intracellular 
content revealed a small peak relative to galangin, and two other minor peaks which could be related 
to metabolites of galangin. The HPLC analysis of extracellular content revealed two peaks, none of 
which was relative to galangin. Comparing these results and the UV spectra of the peaks with the 
data from literature, it seems likely that the unknown peaks revealed in the intra- and extracellular 
contents are related to metabolites of galangin, especially glucuronidated and sulphate forms (Wu et 
al., 2011). Further studies are needed to clearly identify the in vivo metabolites of galangin, and to 
clarify their role and their potential bioactivity in the human organism. 
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Magnolol is a polyphenolic lignan compound isolated from the bark of Magnolia officinalis L., a 
popular Chinese plant used in traditional medicine for the treatment of anxiety, fever and headache 
(Chen et al., 2011). Most of the bioactivities evaluated in vitro for magnolol have been attributed to 
the native form of magnolol, although the analysis regarding the metabolism of this compound has 
shown that it undergoes extensive glucuronidation (Zhu et al., 2012). The pharmacokinetics and 
tissue distribution of magnolol and its metabolites have been studied in various experimental 
conditions, in order to obtain more detailed information about the actual molecules working in vivo. 
Studies from literature were conducted in rats, and the results reveal the presence of metabolites 
after administration of magnolol in vivo (Lin et al., 2011). The results indicated that magnolol-
glucuronide is the major conjugated form present in circulation. The tissue distribution analysis show 
that, despite the high metabolism of the compound, magnolol is the major form in various organs, 
and this is probably due to the metabolic hydrolysis of the glucuronide and sulphate conjugates into 
the cells of the various organs (Lin et al., 2011). The HPLC analysis performed in the present research 
revealed that, in the intra- and extracellular compartments, only one main peak was present. 
Comparing these chromatograms with that of magnolol standard, the only peak found after 
treatment of HT-29 cells with magnolol was magnolol itself. No peaks relative to conjugates or 
metabolites were revealed, suggesting that the metabolism of this compound may be different in 
human cells, than in rats, either for different pharmacokinetic time or for different expression of 
specific enzymes. Additional studies are needed to deepen the research on the potential in vivo 
forms of magnolol and their biological action. 
Myricetin is a polyhydroxylated flavonoid isolated from Myrica rubra S. Z., which is a traditional plant 
from Asia. Several beneficial properties have been attributed to myricetin, especially scavenging and 
antioxidant activities, and the contribution of these activities in vivo have been explored in many 
research. In previous studies, authors evaluated the potential metabolic transformation of 
polyhydroxylated flavonoids, including myricetin, after oral administration in rats (Griffiths & Smith, 
1972). The results showed that the hydroxyl groups in the B-ring of the selected flavonoids were 
susceptible of metabolism, leading to phenolic and phenyl-acetic acids as main products. Lin and 
colleagues also studied the in vivo biotransformation of myricetin in rats, and they identified 
myricetin and its metabolites in the urine, whereas in plasma samples only metabolites were 
revealed (Lin et al., 2012). Few other researches from literature investigated the in vitro cellular 
uptake of flavonoids, including myricetin, using Caco-2 cells as experimental model, with the aim to 
evaluate the ability of the compounds to cross intestinal cell membrane. Although other flavonoid 
aglycones studied were incorporated into Caco-2 cells, myricetin was not detected (Yokomizo & 
Moriwaki, 2006). In the present research, the in vitro cellular uptake of myricetin was evaluated 
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using HT-29 cells as experimental model. The HPLC analysis revealed that no peaks relative to 
myricetin have been found in both the intra- and extracellular compartments. All the wavelengths 
analyzed were scanned but the presence of other peaks relative to possible metabolites of myricetin 
was not detected. These results were similar to that from literature on Caco-2 cells. The authors 
supposed that the reason behind the absence of peaks relative to myricetin or its metabolites might 
have been its instability under the experimental conditions (Miura et al., 1998; Yokomizo & 
Moriwaki, 2006). 
Oleuropein is a polyphenolic compound isolated from the leaf of Olea europea L., and it is one of the 
main phenolic constituents of olive oil. Studies from literature indicate that the consumption of olive 
oil, as seen with the Mediterranean diet, gives low incidence of cardiovascular diseases and certain 
types of cancer (Carluccio et al., 2003; Visioli et al., 2002). Olive oil is a source of at least 30 different 
phenolic compounds, as oleuropein, which possess beneficial properties, like antioxidant activity 
(Carluccio et al., 2003). Many in vitro studies have been performed to identify the bioactivity of the 
polyphenols from olive oil, and the results showed that these compounds possess strong radical 
scavenging activity. Moreover, they also act as inhibitors of LDL oxidation in vitro, and they are able 
to break the peroxidative chain reaction (Bertin et al., 2016; Tripoli et al., 2005). Despite the 
evaluation of the in vitro biological activity, there are not enough data in the literature about the 
biological fate and the absorption of oleuropein. Some authors investigated the absorption of 
oleuropein using an isolated perfuse rat intestine (Edgecombe et al., 2000). The results indicate that 
oleuropein is capable of permeating the intestinal barrier, but the amount of oleuropein that reaches 
the systemic circulation seems very low. The HPLC analysis, performed in the intra- and extracellular 
contents after the treatment of HT-29 cells with oleuropein, indicated that the peak relative to 
oleuropein was present only in the extracellular compartment, and no other peaks were revealed, 
both in intra- and extracellular compartments. During the time frame of the experiments, oleuropein 
was not taken up by HT-29 cells, and no metabolism reactions occurred. This is probably due to the 
high hydrophilic properties of this compound, which has free hydroxyl groups, and this does not 
allow the permeability and passive diffusion of oleuropein across the HT-29 cell membranes. It is 
possible that other reactions occur in vivo on oleuropein before it enters the intestinal lumen, and 
that potential different ways of absorption exist. Therefore, further studies are needed to 
understand how oleuropein interacts with human organism. 
Silybin is a polyphenolic compound and the major active constituent of silymarin, a well known 
flavonolignan complex from Silybum marianum L. The possible therapeutic applications of this 
flavonoid are hampered by its poor enteral absorption, which accounts for its very low bioavailability. 
Silymarin exerts a wide range of biological and pharmacological effects, and in vivo clinical studies 
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evidence and demonstrate clinical efficacy, although the limited oral bioavailability (Wellington & 
Jarvis, 2001). Only 20-50% of oral silymarin is absorbed from the gastrointestinal tract, where it 
undergoes extensive enterohepatic circulation (Wu et al., 2009). It is reported that the limited 
bioavailability of silybin is due to four major causes: extensive phase-II metabolism, low permeability 
across intestinal epithelial cells, low water solubility, and rapid excretion in bile and urine (Javed et 
al., 2011). The results from the present research confirmed the poor uptake of silybin across the HT-
29 cell membranes. The HPLC analysis revealed that silybin was not present inside the cells, since the 
peaks were absent in the intracellular compartment. In the extracellular content, two peaks relative 
to the two isomers of silybin were revealed, thus, silybin was not able to permeate into the HT-29 
cells. Because of the poor bioavailability, recently, authors formulated different kind of complex, in 
order to improve silybin and silymarin in vivo bioavailability (Javed et al., 2011).  
 
5.2. Polyphenols activity against glycation and oxidative stress 
Protein glycation is a non-enzymatic reaction between the carbonyl group of a reducing sugar and 
the free amino group of a protein, leading to the structural and functional changes in the native 
protein. Chronic hyperglycemia can cause non-enzymatic protein glycation because the carbonyl 
group of glucose reacts with the free amino groups of proteins to initiate a complex cascade of 
repeated condensations, rearrangements, oxidative modifications, resulting in the reversible 
formation of a Schiff’s base (Vistoli et al., 2013). This is further rearranged into more stable 
structures called Amadori products, which undergo further oxidation, generating dicarbonyl 
compounds to form cross-linked structures (AGEs). Although an elevated level of glucose had been 
thought to play a primary role in the Maillard reaction, the formation of AGEs is now known to result 
also from the action of various metabolites other than glucose, such as glyoxal and dicarbonyl 
compounds (Sadowska-Bartosz et al., 2014). It has been clearly demonstrated that the accumulation 
of AGEs in body tissue is the leading cause of several age-related degeneration, atherosclerosis and 
diabetic complications such as retinopathy, nephropathy and neuropathy (Vlassara & Palace, 2002). 
For this reason, the inhibition of AGEs formation could represent a therapeutic strategy against 
diabetic complications. 
Aminoguanidine (AG), used as positive control in the present research, is a small synthetic hydrazine-
like compound, well-known for its anti-glycation activity. AG has shown promising results in terms of 
in vitro inhibition of AGE formation, and clinical trials were also conducted. However, AG has shown 
some toxicity reaction in diabetic nephropathy, such as gastrointestinal problems and anemia (Bolton 
et al., 2004). Therefore, the effort has been directed in finding phytochemical compounds from 
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medicinal plants that effectively inhibit protein glycation and AGEs formation. It is well known that 
phenolic compounds have attracted scientific interest because of their antioxidant properties. The 
polyphenols exhibit considerable free radical scavenging activities, through their reactivity as 
hydrogen- or electron-donating agents and metal ion chelating properties (Brewer, 2011; Perron & 
Brumaghim, 2009). The mechanism behind the glycation reaction is linked with oxidation and ROS 
formation, thus the antioxidant properties of polyphenols could represent a strategy against protein 
glycation. A recent study has shown that compounds with combined anti-glycation and antioxidant 
properties, such as aminosalicylic acid, are more effective than aminoguanidine in protecting 
endothelial cells against the harmful effects of high glucose and AGEs in vitro (Duraisamy et al., 
2003). The present study reports the inhibitory effects of selected polyphenols from medicinal plant, 
namely baicalein, eupatorin, galangin, magnolol, myricetin, oleuropein and silybin, on glucose-, 
ribose-, and glyoxal-mediated BSA glycation. These three glycating agents were selected between 
other compounds because of their potential role in hyperglicemic condition and diabetes 
complications. Glucose and ribose are sugars found in vivo in physiological conditions, while glyoxal is 
a high reactive dicarbonyl compound derived from the autoxidation of glucose and from the 
glycation reactions (Wells-Knecht et al., 1995). The data from the present research indicated that the 
glycation induced by glucose determined lower AGEs formation than glyoxal and ribose, suggesting 
that glucose has a slower rate of glycation. This is probably because the rate of Schiff base formation 
is directly proportional to the percentage of sugar in the open chain form. Indeed, the rate of 
glycation for intracellular sugars as glucose-6-phosphate and glyceraldehyde-3-phosphate is 
considerably faster than the rate for glucose (Giardino et al., 1994). The elevated levels of these 
compounds occurring during hyperglycemia would therefore modify circulating and intracellular 
protein. It has been hypothesized that increased glycation of intracellular proteins in endothelial cells 
exposed to diabetic levels of hyperglycemia would result in altered function of proteins that regulate 
endothelial growth (Giardino et al., 1994). Ribose is another naturally occurring sugar present in 
living cells. It is reported that ribosylation is a rapid process that produces AGEs formation and causes 
protein aggregation in vitro and in vivo (Wei et al., 2012). The present research confirms that ribose 
has the faster and stronger ability to induce in vitro glycation and AGEs formation on albumin. During 
diabetes, there is increased intracellular accumulation of dicarbonyl compounds such as glyoxal and 
methylglyoxal (MGO), potent cross-linking agents believed to be of significance in diabetic 
complications (Akhand et al., 2001; Yamawaki & Hara, 2008). In the present research, the effect of 
glyoxal on in vitro BSA glycation was evaluated, as well as its effect on HUVEC. Glyoxal is a highly 
reactive α-oxoaldehyde, endogenously produced via autoxidation of carbohydrates and ascorbate, 
degradation of glycated proteins and lipid peroxidation. AGEs and fructosamine can be oxidized, 
contributing to glyoxal production (Thornalley et al., 1999). Lipid peroxidation is also a potentially 
 - 74 - 
 
important source of glyoxal. The initiation step occurs when polyunsaturated fatty acids such as 
linoleic and linolenic acid undergo nonenzymatic lipid peroxidation. The resulting product is a 
hydroperoxide which then degrades into a variety of products, including glyoxal (Yin & Porter, 2005).  
Studies from literature have shown that most of the glycation inhibitory phytochemicals constituents 
from medicinal plants possess polyphenolic structure. For example, the active glycation inhibitory 
constituents of green tea have been regarded as polyphenols (Peng & Zhang, 2014). Other authors 
suggested the inhibitory capacity of flavonoids against protein glycation, which was remarkably 
related to their scavenging effect on free radicals derived from glycoxidation process (Wu & Yen, 
2005). Moreover, a number of plant derived flavonoids (quercetin, rutin and kaempferol) with 
antioxidant activity have been reported to inhibit glycation, at least in vitro (Vinayagam & Xu, 2015). 
The results from the present research showed that baicalein and eupatorin displayed the best 
antiglycative activity in the BSA-glucose assay and, together with galangin, they were able to 
effectively inhibit AGEs formation in the BSA-ribose assay. The results from the BSA-glyoxal assay 
showed that baicalein and eupatorin inhibited the glycation in a lesser extent, whereas galangin and 
magnolol exerted a strong effect on the glycation reactions and on AGEs formation. Comparing the 
antiglycative activities evaluated in the present research, we can conclude that baicalein and 
eupatorin displayed the strongest inhibitory activity against AGEs formation. Since a correlation 
between tissue AGEs concentrations, protein oxidative modification and the severity of some chronic 
diseases has been demonstrated, the antiglycative activity displayed by baicalein, eupatorin and 
galangin suggest that these natural compounds could be considered promising candidates for further 
studies about their potential effects against glycation.  
Studies have indicated that several factors related to hyperglycemia, dyslipidemia and 
hyperinsulinemia may play roles in the development of diabetes-associated vascular disease and 
atherosclerosis (Creager et al., 2003). A further aim of this research was to examine the effect of the 
factors related to hyperglycemia and diabetes, such as glycated albumin, glyoxal and glucose at high 
concentration on endothelial cells, using HUVEC as experimental model. Among various glycated 
proteins, serum glycated albumin has been reported to be a useful and rapid indicator of glycemic 
control for diabetic patients, since the turnover of serum albumin is much shorter than that of 
glycated hemoglobin (HbA1c). It has been reported a better correlation between gHSA in patients 
with type 2 diabetes with various parameters of glycemic profiles than HbA1c, therefore gHSA could 
be a more accurate marker for evaluating glycemic control (Inaba et al., 2007). Thus, it is important 
to study the effect of glycated albumin, because it could play an important role in diabetes-associate 
vascular disease. 
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Endothelial cells up-regulate the expression of the adhesion molecules in response to NF-kB signaling 
activation, for the recruitment of leukocytes as one of the major events in the development of 
inflammation. VCAM-1 mediates leukocyte-endothelial cell adhesion and signal transduction, and 
may play a role in the development of atherosclerosis and other inflammatory diseases (Cook-Mills 
et al., 2011). Thus, VCAM-1 signaling is a target for intervention by pharmacological agents and by 
antioxidants during inflammatory diseases. In this work, flowcytometry was used to detect the pro-
inflammatory cell adhesion proteins VCAM-1 in HUVECtert. The results showed that glycated albumin 
had not the effect of VCAM-1 expression inducer, suggesting that gHSA do not exert this pro-
inflammatory activity. Many types of study, ranging from in vitro experiments to epidemiological 
studies, have shown that AGEs could play a central role in the pathogenesis of accelerated 
atherosclerosis in diabetes (Basta et al., 2004). Indeed, AGEs and their receptor (RAGE) interaction 
evokes oxidative stress generation and vascular inflammation (Goldin et al., 2006). The experimental 
results obtained in this work showed that the early product of glycation gHSA had not the same 
effect reported in literature about AGEs, and it is not directly involved in the pro-inflammatory 
activation of HUVEC. Concerning the oxidative stress, the results obtained showed that gHSA did not 
display a pro-oxidant effect in HUVEC. Many studies from literature proposed that the damaging 
effect of AGEs is predominantly induced by RAGE signaling thus increasing ROS formation and 
inflammatory processes (Ott et al., 2014). Glycated-HSA, which is an early glycation product mainly 
composed of fructosamine, seems to have a very different effect than the advanced glycation end 
products AGEs (Thornalley et al., 1999). This could be mainly due to the differences of structure and 
reactivity between the different glycation products (Paradela-Dobarro et al., 2016). In the literature, 
there are several studies reporting the effect of glycated albumin in vasculature (Basta et al., 2002; 
Higai et al., 2006; Rubenstein et al., 2010). However, some critical aspects about these works must be 
considered. Many studies used AGEs prepared in vitro by incubating a protein, often albumin, with a 
reducing sugar or dicarbonyl compound, using however different parameters as concentrations of 
albumin and sugar, incubation time, analysis of the final products. Therefore the final products can 
be vary and different, and the effect experimentally detected can be produced by various agents as 
AGEs, Amadori products or even other modification products. Without knowing the exact nature of 
the products involved, it is difficult to determine the distinct role of each glycation product in 
diabetes-associated vascular complications. The glycated albumin used in this research work is an 
early glycation product which has a degree of substitution expressed as 1-5 mol of hexose (as 
fructosamine) per mol of albumin. The present study showed that the early glycated product, such as 
gHSA, is not responsible of increased oxidative stress in HUVEC during the two hours of incubation. 
Moreover, a potential effect of gHSA on the viability of endothelial cells was evaluated. The results 
showed that gHSA has not cytotoxic activity, but conversely a slight proliferative effect in cultured 
 - 76 - 
 
HUVEC. In order to better understand the vascular complications associated with diabetes, the link 
between glycation and angiogenesis has been explored in several researches. Recently, it has been 
demonstrated that AGEs induce a significant increase in the number of viable skin microvascular 
endothelial cells and that this effect is mainly mediated by the paracrine secretion of VEGF (Roca et 
al., 2014). These effects seem to be due to RAGE activation. However, the effects of AGEs on 
angiogenesis are not that straightforward. While endothelial cells stimulation by AGE-BSA or -HSA 
seems to increase VEGF expression, capillary tube formation and promote angiogenesis, some types 
of AGEs appear to exert the opposite effect. Glycation seems to be involved in this paradox because 
it is both proangiogenic (with the ability to activate inflammation and ROS production pathways) and 
antiangiogenic (glycated extracellular matrix proteins result in an unfavorable environment for 
angiogenesis). Further, pro- and anti-angiogenic factors are proteins which can also be glycated (Roca 
et al., 2014). In a prolonged hyperglycemic condition, the glycation of growth factors could modify 
their respective activities, impairing the angiogenesis. The results from the present study revealed 
that gHSA could have a pro-angiogenic effect on HUVEC; these data have to be still study in deep to 
learn more about the molecular mechanisms involved in these events.  
During hyperglycemia and diabetes, there are high blood glucose levels as well as fluctuation in 
glucose concentration. This condition has been linked to vascular disease and endothelial 
dysfunction. High glucose levels in circulation promote glycation process and the formation of the 
reactive α-oxoaldehydes glyoxal and methylglyoxal (Ott et al., 2014). Glyoxal is the most prominent 
reactive α-oxoaldehyde, together with methylglyoxal, derived from glucose oxidation, lipid 
peroxidation, and glycation reaction. Glyoxal can furthermore react with different amino acid 
residues of protein targets becoming a further cause of AGEs formation (Sliman et al., 2010; 
Thornalley et al., 1999). Glycation during hyperglycemic conditions and oxidative stress-mediated 
lipid peroxidation contribute to the formation of reactive carbonyl species (RCS) and induction of 
carbonyl stress. Oxidative stress plays a major role in the development of micro- and macrovascular 
complications of diabetes. Accumulation of free radicals in the vasculature of diabetic patients is 
responsible for the activation of redox signaling and epigenetic changes contributing to vascular 
inflammation and ROS generation (Creager et al., 2003). Reduction in cellular viability and increased 
oxidative stress can lead to endothelial dysfunction; therefore, in this study we evaluated the effect 
of glyoxal and high glucose on HUVEC viability and ROS formation. Studies from literature revealed 
that glyoxal cause detrimental effect in vasculature seen as cytotoxicity, barrier dysfunction and 
inhibition of angiogenesis in bovine pulmonary artery endothelial cells (Sliman et al., 2010). In the 
present study, glyoxal displayed cytotoxic activity seen as reduction in HUVEC viability after 24 hours 
of incubation. Glucose at high concentration did not display a direct cytotoxic activity on HUVEC, but 
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the mechanism by which it contributes to endothelial dysfunction is reported to be mainly related to 
oxidative stress and ROS formation (Quagliaro et al., 2005). Therefore, the activity on ROS formation 
in HUVEC has been the subsequent effect evaluated in the present research. The experimental study 
using DCFH-DA assay did not show a direct effect of glyoxal on ROS formation, during the 24 hours of 
incubation. Thus the cytotoxic effect of glyoxal on HUVEC is not directly related to oxidative stress, 
and further studies are needed to find the molecular mechanisms involved in the negative effect of 
glycation-derived dicarbonyl compounds. As reported in the literature, GO seems to determine 
changes in HUVEC morphology after 24 h treatment, and to examine whether the morphological 
changes are associated with vascular inflammatory states, the expression of inflammation-related 
proteins was measured. Chronic treatment of HUVEC with GO (500 μM, 24 h) induced COX-2 protein 
expression, but not VCAM-1 expression (Yamawaki & Hara, 2008). Overproduction of ROS by 
mitochondria is considered as a causal link between elevated glucose and the major biochemical 
pathways involved in the development of vascular complications of diabetes. The high levels of 
glucose are proposed to mediate pathological effects in vascular cells through the production of ROS. 
Cells cultured in high glucose and cells from diabetic subjects have been shown to release higher 
levels of ROS (Pitocco et al., 2013). Several mechanisms have been proposed for this increased ROS 
production, such as the mitochondrial electron transport chain, the advanced glycation end products 
and the PKC-dependent activation of NAD(P)H oxidase. The results obtained in this research work 
confirmed the data from literature, showing an increase of ROS formation in HUVEC cells after the 
treatment with high glucose. 
Considering the harmful effect of glucose at high concentration on ROS production and oxidative 
stress in endothelial cells, antioxidant therapy may be an interesting choice to reduce diabetes-
mediated vascular abnormalities. Previous studies showed that there is an improved endothelium-
dependent relaxant response with various antioxidant agents, including superoxide dismutase (SOD) 
(Voinea et al., 2004). Thus, antioxidant approach is an option that could be used in combination with 
other therapies to treat vascular diseases. Natural compounds from medicinal plants have received 
particular attention in the context of the antioxidant activity. In recent decades, herbal remedies and 
natural products have undisputedly attracted much research attention in the context of prevention 
and treatment of cardiovascular and metabolic diseases. Polyphenols are secondary metabolites of 
plants and are generally involved in defense against ultraviolet radiation or aggression by pathogens. 
In the last decade, there has been much interest in the potential health benefits of plant polyphenols 
as antioxidants. The antioxidant activity of polyphenols is characterized by the phenolic structure; 
however, different classes of polyphenols may have different significant effects on vascular disease 
as evidenced by the study done by Loke and colleagues (Loke et al., 2010). In the present work, the 
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polyphenols studied for their antioxidant activity in in vitro endothelial cells were baicalein, 
eupatorin and galangin. These natural compounds have been chosen from a larger group of 
polyphenols from medicinal plants widely used in traditional medicine. It has been found that 
baicalein, eupatorin and galangin display a good in vitro antioxidant activity in DPPH and ORAC assay 
(Bertin et al., 2016) and the results from the glycation assay, described in the “Results” chapter, 
showed that these three phytocompounds determined the best inhibitory activity of protein 
glycation induced by glucose and glyoxal.  
Regarding the activity of baicalein and eupatorin on the TNFα-induced VCAM-1 expression, the 
results showed that only eupatorin displayed the inhibitory activity, at both the concentration tested 
of 5 and 10 μM. In the literature is reported that the effect on adhesion molecule expression was 
strongly dependent on the chemical structure of the flavonoids (Lotito & Frei, 2006). These were 
previously reported to prevent adhesion molecule expression in endothelial cells, and that flavonols, 
as apigenin, are the most effective flavonoids in inhibiting cytokine-induced expression of E-selectin, 
ICAM-1, and VCAM-1 in HUVEC (Gerritsen et al., 1995). Specific research from literature about the 
structure-relation activity of flavonoids found that flavanones and flavanol were not able to inhibit 
adhesion molecule expression, whereas hydroxyl flavones and flavanols displayed the strongest 
inhibitory activity (Lotito & Frei, 2006). The results from the present research showed that eupatorin, 
a polymethoxylated flavone, was more effective in inhibiting the VCAM-1 expression on HUVEC than 
baicalein, a hydroxyl flavone. Differently it happened for the antioxidant activity. It is reported that 
baicalein is a potent antioxidant agent, and displays anti-inflammatory properties in vitro and in vivo 
(Shen et al., 2003; Tsai et al., 2014). Evidences indicate that baicalein has multiple biological 
activities, including cardioprotective and neuroprotecive (Chang et al., 2011; Zhang et al., 2012). 
Studies from literature suggested that the mechanisms of action underlying these protective effects 
are mainly associated with antioxidant activity, which has been evaluated as inhibition of lipid 
peroxidation, up-regulation of HO-1, and activation of Nrf-2 (Im et al., 2005; Zhang et al., 2012). In 
the present research, ROS determination assay was performed on HUVEC, and the results showed 
that baicalein was able to inhibit the ROS production in HUVEC in basal condition. Baicalein displayed 
also antioxidant activity against the oxidative stress induced in HUVEC by high glucose, reducing the 
ROS formation at both the concentration tested of 1 and 5 μM. Data from literature show that 
galangin protects in vitro cultured cells from cytotoxicity and oxidative stress induced by glutamate, 
low levels of glutathione, and glucose starvation in culture medium, and that these activities could be 
attributed to the three hydroxyl groups of this compound. The effects seen for galangin have been 
attributed to its antioxidant activity (Ishige et al., 2001). In the present research, galangin displayed a 
good antioxidant activity against the ROS formation in HUVEC, both in basal condition and after high 
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glucose-induced oxidative stress. Conversely, eupatorin was not able to inhibit the ROS production in 
HUVEC in basal condition. However, after the induction of oxidative stress by high glucose, eupatorin 
5 μM displayed antioxidant effect seen as inhibition of ROS formation. The differences in the 
structure of selected polyphenols are represented by the hydroxyl groups of baicalein and galangin, 
and the methoxyl groups of eupatorin, suggesting that the free hydroxyl groups lead to antioxidant 
activity. 
In conclusion, the results showed that high glucose could have an important role in vascular 
complication caused by hyperglycemia and diabetes. The mechanisms behind glycation-related 
pathologies are very complex, and the activity of glycated albumin and glyoxal have to be further 
evaluated.  
Regarding the activity of polyphenols, the results suggest that baicalein, eupatorin and galangin have 
high antioxidant and antiglycative activities against in vitro glycation of albumin (BSA), and the 
antioxidant activity has been displayed also in cultured HUVEC. Baicalein and galangin effectively 
decrease the ROS formation induced by high glucose on HUVEC, whereas the most important activity 
of eupatorin was the anti-inflammatory activity against the TNFα-induced VCAM-1 expression. Thus, 
these natural compounds may represent promising candidates for more detailed studies about their 
potential effects against glycation and oxidative stress related to vascular diseases. 
All together, the results obtained motivate further researches on the activities of natural polyphenols 
against oxidative and glycative damages in order to understand their potential and actual role in the 
prevention of diabetes-related vascular diseases.  
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